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Overall Abstract 
A previous study of 100 methicillin-resistant Staphylococcus aureus (MRSA) isolates, 
collected between January 2007 and December 2008 from five Cape Town hospitals, 
identified ST612-MRSA-IV as the predominant MRSA. This raised the question of whether 
methicillin-susceptible S. aureus (MSSA) isolates with the same sequence type (ST) were 
present in hospitals in this city. Nineteen MSSA isolates, collected during the same period, 
and from four of the hospitals in Cape Town, as the previously characterized MRSA isolates, 
were screened for the presence of ST612-MSSA. spa typing and multi-locus sequence typing 
(MLST) identified one isolate, MS14, as ST612-MSSA, spa type t064. 
MS14 was resistant to multiple antibiotics, including rifampicin, as was observed in ST612-
MRSA-IV. Characterization of MS14 identified remnants of SCCmec, within the attB site, 
which included the dcs region 1.7kb downstream of orfX. An investigation of the mechanism 
of rifampicin resistance in MS14 showed that the resistant isolates and MS14 share an 
uncommon rpoB genotype, and a unique single nucleotide mutation within this gene, 
suggesting that MS14 resulted from a partial loss of SCCmec from a corresponding ST612-
MRSA strain.   
As studies have shown that the carriage of SCCmec may impose a fitness cost on its host, 
MS14 was competed against four representative ST612-MRSA-IV isolates in 24-hour and 
five-day pairwise assays. Three of the resistant strains were outcompeted by MS14, 
suggesting that the carriage of SCCmec IV may impose a fitness cost on these isolates. On 
the other hand, the remaining resistant isolate competed successfully with MS14, 
suggesting that it may have evolved to accommodate the presence of SCCmec IV in its 
genome.  
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1.1 Staphylococci: Bacteriology 
 
Staphylococci are Gram positive, facultative anaerobic cocci which form golden or white 
colonies on nutrient agar. Gram stain microscopy reveals singles, pairs, tetrads, short chains 
or irregular ‘grape-like’ clusters of the cocci. Members of this genus are part of the normal 
microflora inhabiting skin, skin glands and mucous membranes of mammals, although they 
have occasionally been isolated from birds as well. Staphylococci are traditionally classified 
based on their ability to produce coagulase, an extracellular protein that facilitates clotting 
of blood plasma. Of over 32 species belonging to this genus, at least five species including 
Staphylococcus aureus and Staphylococcus intermedius have been identified as coagulase-
positive while the rest are coagulase-negative (Kloos 1998).  
S. aureus is an opportunistic pathogen causing infections in both immuno-competent and 
immuno-compromised individuals. This organism is carried mainly in the nasal cavity but can 
also be present on the skin, in the skin glands, in the oral cavity as well as in the 
gastrointestinal tract. It has been suggested that S. aureus may be carried asymptomatically 
in 20% of individuals at any given time, and transiently in 60% of the population, while the 
remaining 20% is rarely or never colonised (von Eiff, Becker et al. 2001; Pynnonen, 
Stephenson et al. 2011).   
Colonisation by S. aureus provides a reservoir for subsequent infection if the host’s defences 
are breached. Colonisation is a complex process that involves the host’s interaction with S. 
aureus and the ability of the bacteria to adhere to the host’s cells and to evade immune 
detection. A break in the skin or the mucous barrier predisposes to simple skin infections or 
serious life threatening infections such as pneumonia, meningitis, osteomyelitis, 
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endocarditis, toxic shock syndrome (TSS), bacteremia and sepsis, both in the community and 
hospitals (Kloos 1998; Noble 1998; Gordon and Lowy 2008).  
Coagulase-negative staphylococci (CNS) are generally less pathogenic than S. aureus 
however, some species are potentially pathogenic particularly to immuno-compromised 
individuals. Minor infections such as Staphylococcus saprophyticus urinary tract infections 
(UTIs) in males and females have been described. On the other hand, Staphylococcus 
epidermidis can be the cause of life threatening infections such as endocarditis which is 
often associated with implantation of foreign devices (Noble 1998; Petti, Simmon et al. 
2008).  
1.2 Virulence factors of S. aureus and their role in pathogenesis  
 
Pathogenesis of infection is facilitated by a host of virulence factors which can be both 
structural and secreted products of S. aureus. In establishing infection, S. aureus utilises its 
surface proteins called “microbial surface components recognizing adhesive matrix 
molecules” (MSCRAMMs) which mediate adherence to host tissues (Foster and Hook 1998; 
Gordon and Lowy 2008). These recognise and bind several host factors such as fibrinogen, 
fibronectin, and collage  while different MSCRAMMs may adhere to the same host-tissue 
component. 
MSCRAMMs are expressed early in infection in order to initiate colonisation of specific 
tissue sites with S. aureus. To facilitate spread, a host of toxins are released, including 
enzymes such as proteases, lipases and elastases which are useful in host cell invasion and 
damage as well as the spread of S. aureus. Also critical in pathogenesis is the release of 
proteins that inhibit chemotaxis, resulting in impairment of the mechanisms of recruitment 
of macrophages as well as neutrophils to the site of infection (Fig1.1). Another role player in 
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immune evasion is the release of leukocidins such as the Panton-Valentine leukocidin (PVL), 
which punctures holes in the membranes of leukocytes (Gordon and Lowy 2008). 
           
Figure 1.1: A diagrammatic representation, adopted from Nizet (2007), of S .aureus mechanisms of innate 
immune resistance by production of adherence factors that adhere to the host tissues and release of virulence 
factors that interfere with the host’s defences.  
To avoid metabolic stress in the organism, expression and release of virulence factors is 
controlled by cell density, energy availability and environmental signals (Novick 2003). 
Expression of MSCRAMMs occurs during the exponential growth phase while toxins are 
released during the stationary phase (Gordon and Lowy 2008). There are several 
mechanisms that S. aureus uses for regulation of the expression of its virulence factors. For 
instance, the accessory gene regulator (agr), which works in conjunction with,  or 
antagonistically to, two-component systems, such as sae, arlRS and srrAB/srhSR, plays a key 
role in a complex regulatory network involved in the signalling pathway for the regulation of 
the virulence factors (Novick 2003). agr is a quorum-sensing system which responds to 
signals from the external environment and coupled with the energy metabolism of the cell, 
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facilitates global regulation of a subset of the virulence factors in a time and quantity 
dependent manner (Novick 2003).  
It is important to note that not all S. aureus strains have the same repertoire of virulence 
genes; in fact, certain clones are associated with particular virulence genes (Gordon and 
Lowy 2008). For instance, PVL, encoded by lukF-PV and lukS-PV genes located on at least 
eight different phages (Zhang, Ito et al. 2011), has been associated with hypervirulent 
community associated methicillin-resistant S. aureus (CA-MRSA) strains.  These 
hypervirulent CA-MRSA, such as USA400, are associated with life threatening infections such 
as necrotising pneumonia even in previously healthy individuals (Vandenesch, Naimi et al. 
2003; Monecke, Coombs et al. 2011).  
1.3 Overview of antibiotic resistance in S. aureus 
Over the past few decades, there has been an increase in the occurrence of multi-drug 
resistant S. aureus strains, identified both in the community and in health care settings 
(Lyon and Skurray 1987; Enright, Robinson et al. 2002; Deurenberg and Stobberingh 2008; 
Boucher and Corey 2008). Emergence of antibiotic resistance in bacteria is attributed to the 
selective pressure imposed by antibiotic therapy (Lyon and Skurray 1987). This is evidenced 
by the emergence of resistance following the introduction of an antibiotic into clinical use 
(Clatworthy, Pierson et al. 2007).  
One of the factors which has made S. aureus a successful human pathogen is the ability of 
the bacteria to adapt to a wide range of antibiotics (Nübel, Dordel et al. 2010). Table 1.1 
outlines mechanisms of resistance of S. aureus to some clinically useful antibiotics.  
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Table 1.1: Mechanisms of resistance to some clinically useful antibiotics in S. aureus.  
Antibiotic Class  Target 
 
Resistance mechanism Location  
Benzyl- penicillins  
(penicillin) 
 
 
Semi-synthetic 
penicillins (methicillin) 
 
 
β-lactams 
 
PBPs 
 
Production of β-lactamase (BlaZ) 
which hydrolyses the β-lactam 
nucleus  
Plasmid: 
Transposon 
Synthesis of acquired PBP2a 
(MecA) which has reduced affinity 
for semi-synthetic β-lactams 
Chromosome
: SCCmec  
Erythromycin  
 
Clindamycin 
 
Streptogramin B 
Macrolide 
 
Lincosamide 
 
Streptogramins 
23SrRNA Methylation of the 23SrRNA 
ribosomal subunit by 
erythromycin ribosomal 
methylases (ErmA, B, C) reduces 
its affinity for erythromycin, 
clindamycin and streptogramin B. 
Plasmid, 
Chromosome 
 
 
 
 
 
Rifampicin Rifamycins RpoB Modification of the RNA 
polymerase due to amino acid 
substitutions in the β-subunit 
reduces its affinity for rifamycins 
 
Chromosome 
Ciprofloxacin  Fluoroquinolone  Gyrases (GyrA, B) 
 
Topoisomerase IV 
(GrlA) 
Mutations in the targets reduce 
their affinity for fluoroquinolones 
Chromosome 
Target 
independent 
Overexpression of NorA results in 
active efflux of fluoroquinolones. 
Chromosome 
Vancomycin  Glycopeptide  D-Ala-D-Ala Altered cross-linking of 
peptidoglycan results in an 
increase in the quantities of D-Ala-
D-Ala residues exposed to 
vancomycin. Excess dipeptides 
bind and trap vancomycin in the 
cell wall but do not interfere with 
cell wall synthesis. 
 
 
Synthesis of peptidoglycan 
precursors terminating in D-Ala-D-
Lac (vanA operon), which have 
reduced affinity for vancomycin.  
 
Chromosome 
 
 
 
 
 
 
 
 
 Plasmid: 
Transposon 
Linezolid  Oxazolidine 23SrRNA 
 
Modifications in domain V of the 
23SrRNA of the 50S ribosomal 
subunit, either by mutations or by 
products of cfr, result in decreased 
affinity for the antibiotic. 
 
Plasmid, 
Chromosome 
Prepared from data derived from Walsh (2003), Lowy (2003), Lyon and Skurray (1987), Kaatz, Seo et al. (1993) 
Markham and Neyfakh (1996), Mrales, Picazo et al. (2010) and LaMarre, Locke et al. (2011) . 
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As the studies described in this thesis relate to methicillin-resistant S. aureus (MRSA), 
resistance to β-lactams, and methicillin in particular, will be described more fully. 
1.3.1 Resistance to β-lactams in S. aureus 
Resistance to β-lactams in S. aureus was reported in 1942, two years after the introduction 
of penicillin into clinical use. It has since been reported that 80% of all S. aureus strains are 
resistant to penicillin (Deurenberg and Stobberingh 2008). β-lactams inhibit cell wall 
synthesis by binding to penicillin binding proteins, PBPs, transpeptidases and 
carboxypeptidases which catalyse cross-linking of peptidoglycan during cell wall synthesis 
(Essack 2001).  
β-lactams have a four-atom ring, the β-lactam ring, common to all β-lactams including 
penicillins and cephalosporins (Fig 1.2).  
 
Figure 1.2: The core structure of some major classes of β-lactam antibiotics. Adopted from Andersson, et al. 
(2001). 
 
This β-lactam ring is the basic structure of monobactams and is the nucleus of all β-lactams, 
where it can be fused to a five-membered thiazolidine ring as in the case of penicillins, or to 
a six-membered dihydrothiazine ring as in cephalosporins (Fig 1.2) (Andersson, Terwisscha 
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van Scheltinga et al. 2001). The β-lactam ring is the chemically reactive moiety of the 
antibiotic as it acylates the serine side chains in the active sites of PBPs. As β-lactams are 
pseudo-substrates for PBPs, the hydrolysis of the β-lactam ring is partial, blocking the active 
site of the PBPs, thus inhibiting activity of the enzymes in the cross-linking of peptidoglycan 
(Walsh 2003). 
One mechanism of resistance to penicillin in S. aureus is through the production of an 
extracellular penicillin-specific β-lactamase, penicillinase, which hydrolyses the β-lactam ring 
of benzyl-penicillins. Penicillinase is a serine β-lactamase, so called due to the serine-
dependent catalytic mechanism of the enzyme. Genes encoding these enzymes in S. aureus 
can be either plasmid (blaZ) or chromosomally (PC1) located (Lyon and Skurray 1987; Hall 
and Barlow 2004).  
Expression of BlaZ is regulated by a repressor BlaI and a transmemberane transducer BlaR1. 
In the absence of penicillin, BlaI represses the transcription of blaZ and blaR1-blaI. In the 
presence of penicillin, BlaR1 is autoactivated and cleaves BlaI thereby releasing it from the 
blaZ operator region. With the cleavage of BlaI, blaZ is transcribed, resulting in the 
hydrolysis of the antibiotic in the extracellular space (Lyon and Skurray 1987; Lowy 2003). 
In the early 1960s, penicillinase resistant semi-synthetic penicillins, such as methicillin, were 
introduced for the treatment of S. aureus infections (Noble 1998). Semi-synthetic penicillins 
are structural analogues of the benzyl-penicillins with modifications to the core β-lactam 
structure (Fig 1.3).  
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Figure 1.3: The differences in the structural modifications on the side chains of penicillins which determine 
susceptibility of the antibiotics to β-lacatamses. Adapted from O’Callaghan (1980). 
 
These modifications to the β-lactam nucleus, such as, direct linking of a bulky side chain to 
the carbon (Fig 1.3), replacing the sulphur by a carbon or, the enlargement of the fused ring 
to a six-membered heterocyclic ring, as in the case of caphalosporins, increase sterric 
hindrance that inhibits binding of the penicillinase, which the less bulky penicillinase 
susceptible penicillins are unable to prevent (Walsh 2003; O'Callaghan 1980).   
1.3.1.1 Resistance to methicillin 
Soon after the introduction of methicillin into clinical use, resistance to this antibiotic was 
reported in some clinical isolates of S. aureus (Rolinson 1961; Çetin and Ang 1962; Noble 
1998; Enright, Robinson et al. 2002; Deurenberg and Stobberingh 2008). Resistance to 
methicillin follows the acquisition of mecA, which encodes PBP2a (PBP2’), a penicillin 
binding protein that has a low affinity for methicillin, enabling cell-wall synthesis to 
continue. The mecA gene is embedded in a large genetic element (20kb to 64kb) called the 
Staphylococcal cassette chromosome mec (SCCmec). This element is integrated at attB, an 
integration site at the 3’end of an open reading frame, orfX, a conserved region that 
encodes a 23s rRNA methyltransferase in S. aureus (Shore, Deasy et al. 2011).  
Core penicillin 
structure 
Penicillinase 
resistant 
penicillins 
Penicillinase 
susceptible 
penicillins  
Methicillin 
Oxacillin 
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1.3.1.1.1 Integration of SCCmec 
 
Integration of SCCmec at the attB site is mediated by site specific recombinase enzymes, 
CcrA, CcrB and CcrC, encoded by the cassette chromosome recombinase gene, ccr. CcrA and 
CcrB are members of the serine resolvase and invertase family and contain catalytic and 
DNA-binding domains; the former can act as both an integrase and an excisase. For 
integration, the recombinase enzymes recognize a core 15bp nucleotide sequence, present 
in attB, which is then recombined with a homologous sequence (attS) on SCCmec (Fig 1.4). 
After recombination, the attachment sites are duplicated on either side of the SCCmec to 
create left (attL) and right (attR) junctions between SCCmec and the chromosome 
(Katayama, Ito et al. 2000; Noto and Archer 2006; Noto, Kreiswirth et al. 2008; Wang and 
Archer 2010). 
attS
SCCmec
attRattL
attB
mec complex ccr complex
orfX
orfX
ccr complex mec complex
Integrated SCCmec
Ccr mediated integration
Chromosome
 
Figure 1.4: Integration of SCCmec at the attB site on the S. aureus chromosome. The recombinase enzymes 
encoded by the ccr recognize the homologous 15bp sequences on the SCCmec (attS) and the chromosome 
(attB). Following recombination, the 15bp sequences, attR and attL flank the SCCmec to create left and right 
junctions between SCCmec and the chromosome. 
While the 15bp nucleotide core sequence of attB plays a key role in the integration of 
SCCmec, Noto, et al. (2008) considered the importance of DNA sequences outside of attB, in 
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the non-orfX side, in recombinase functionality. DNA sequences, contiguous with attB in the 
non-orfX region, from MSSA NCTC 8325 and five MRSA strains (MRSA COL, N315, NRS384, 
J39 and MRSA252) known to respond positively to Ccr-mediated recombinations, and from 
MRSA MW2, which contains SCCmec that cannot be excised, were used as comparators 
(Noto, Kreiswirth et al. 2008). The sequences (102bp) of MSSA NCTC 8325 and four of the 
MRSA were identical. A portion of this sequence (12bp), next to attB, is present in 
MRSA252; MRSA MW2 does not contain the conserved sequence. Of the 11 MSSA included 
in the comparison, only one shared the sequence (12bp) conserved in MRSA252. The 
authors concluded that the attB flanking sequence in the non-orfX region may play a role in 
the functionality of Ccr and therefore the acquisition of SCCmec. Important, also, was the 
observation that attB was not only a frequent site for the acquisition of foreign DNA, other 
than SCCmec, but also a ‘hot spot’ for recombination events and rearrangements of 
acquired sequences (Noto, Kreiswirth et al. 2008). 
1.3.1.1.2 SCCmec types 
 
To the best of the author’s knowledge, eleven SCCmec types (I-XI) have been identified and 
extensively characterized in S. aureus (Ito, Katayama et al. 2001; Ito, Ma et al. 2004; Oliveira, 
Milheirico et al. 2006; Higuchi, Takano et al. 2008; Zhang, McClure et al. 2009; IWG-SCC 
2009; Shore, Deasy et al. 2011; Garcia-Alvarez, Holden et al. 2011). The diversity in the 
genetic organisation of the different SCCmec types is classified based on the different 
classes of the mec gene complex (A,B, D, C1, C2, D and E), allotypes of the ccr gene complex 
(1, 2, 3-8) and the components of the junkyard regions (J1-3) (Ito, Katayama et al. 2001; 
Oliveira and de Lencastre 2002; Zhang, McClure et al. 2009; Shore, Deasy et al. 2011; Garcia-
Alvarez, Holden et al. 2011). 
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1.4 Epidemiology of S. aureus 
S. aureus has been reported as a leading cause of hospital-acquired infections, resulting in 
disease in 2% of all newly admitted patients (Nubel, Roumagnac et al. 2008).   It has been 
reported that 400 000 patients contract S. aureus infections in American health-care 
settings every year (Boucher and Corey 2008). In recent years, MRSA has also established 
itself as a common cause of community-acquired infections in persons who do not have 
health-care associated risks (Grundmann, Aires-de-Sousa et al. 2006).  
1.4.1 Molecular tools to study the epidemiology of S. aureus 
Molecular epidemiological analyses of S. aureus have played a key role in the understanding 
of both the local and global epidemiology of MRSA (Bannerman, Hancock et al. 1995; 
Enright, Day et al. 2000; Oliveira and de Lencastre 2002; Enright, Robinson et al. 2002; 
Harmsen, Claus et al. 2003; Strommenger, Kettlitz et al. 2006; Grundmann, Aires-de-Sousa 
et al. 2006; Goering, Shawar et al. 2008).  Several typing techniques have been developed 
for the molecular characterisation of S. aureus. These techniques are generally based on 
either DNA sequences or gel electrophoresis profiles.  The choice of typing technique 
depends on the discriminative power of the technique and the information required. In 
order to study the molecular evolution of S. aureus on a global level, DNA sequence based 
tests, including multi-locus sequence typing (MLST), are ideal. This approach facilitates 
standardisation of test protocols which further enables the adoption of a common 
nomenclature. The data generated can therefore be synchronised to a central database and 
be shared between laboratories (Harmsen, Claus et al. 2003). For the investigation of 
hospital outbreaks or hospital to hospital transmission of S. aureus, a highly discriminative 
tool, such as pulsed field gel electrophoresis (PFGE), is required. This technique has been 
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considered the gold standard for such studies (Koreen, Ramaswamy et al. 2004; Deurenberg 
and Stobberingh 2008). 
1.4.1.1 Pulsed field gel electrophoresis (PFGE) 
In PFGE, following the digestion of S. aureus intact DNA with SmaI, which recognises and 
cleaves at a few sites on the chromosome, the resulting fragments, being too large to be 
separated by conventional agarose gel electrophoresis, are separated by agarose gel 
electrophoresis in an electric field with an alternating voltage gradient (Bannerman, 
Hancock et al. 1995; Deurenberg and Stobberingh 2008). The banding patterns obtained are 
then analysed using a variety of dedicated software packages to determine the relatedness 
between strains. Alternatively, visual inspection of the PFGE patterns, as described by 
Tenover, Arbeit et al (1994), has been used to analyse profiles. Based on the differerences in 
the number of bands, isolates are determined to be either related or unrelated. The fact 
that PFGE is based on the comparison of whole genomes of the isolates makes it invaluable 
in indexing genotypic variations that accumulate rapidly (Bannerman, Hancock et al. 1995; 
Koreen, Ramaswamy et al. 2004).  The limitations of the technique include the lack of 
standardisation of protocols that prevents inter-laboratory comparison of data (Bannerman, 
Hancock et al. 1995; Enright, Day et al. 2000; Deurenberg and Stobberingh 2008), limiting 
the usefulness of the technique to local outbreak investigations. 
1.4.1.2 Multi-locus sequence typing (MLST) 
MLST is based on the DNA sequences of internal fragments of seven highly conserved 
housekeeping genes which are listed on Table 1.2 (Enright, Day et al. 2000; Enright, 
Robinson et al. 2002; Deurenberg and Stobberingh 2008).  
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Table 1.2 The seven loci that are used to define the sequence type (ST) of S. aureus strains 
Gene  Protein product 
arcC  Carbamate kinase 
aroE Shikimate dehydrogenase 
glpF  Glycerol kinase 
gmk  Guanylate kinase 
pta  Phosphate acetyltransferase 
tpi Triosephosphate isomerase 
yqiL Acetyl coenzyme A acetyltransferase 
 
MLST is a three step process: 1) PCR amplification of the internal fragments of each of the 
seven loci; 2) sequencing of the amplicons; and 3) analysis of the sequencing data on the 
MLST website (http://saureus.mlst.net/). For each locus, the sequence is assigned a unique 
allele number. For each isolate, the seven allele numbers for the seven loci generate an 
allelic profile which defines the sequence type (ST) for the strain (Enright, Day et al. 2000; 
Enright, Robinson et al. 2002). To establish evolutionary relatedness between different 
strains, the STs are further organised into clonal complexes (CCs). This is achieved by using 
the algorithm ‘based upon related sequences (BURST)’, which is linked to the MLST website 
(www.eburst.mlst.net). BURST is a user-defined algorithm in which the user defines the 
similarity threshold that clusters related STs into a CC. The most widely accepted threshold 
clusters any strains with ST of single or double locus variants of a founding member of a CC 
in the same CC. This then allows for further understanding of the evolutionary patterns 
within a particular S. aureus population (Enright, Robinson et al. 2002; Deurenberg and 
Stobberingh 2008).  
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1.4.1.3 spa typing 
A strain typing technique that is efficient for the study of both local outbreaks and the 
molecular evolution of strains of S. aureus would be invaluable. It has been reported that 
spa typing, based on amplification and sequencing of the variable region of the spa gene 
encoding protein A, has the potential to index  both the micro- and macro-variations 
required for long-term and short-term epidemiological studies respectively (Koreen, 
Ramaswamy et al. 2004; Deurenberg and Stobberingh 2008). 
The gene (spa) encoding protein A consists of a hypervariable region flanked by conserved 
sequences. The variable region is comprised of variable repeats where variation results from 
deletions, substitutions, duplications or point mutations (Shopsin, Gomez et al. 1999; 
Strommenger, Kettlitz et al. 2006). spa typing involves the amplification of the variable 
region and subsequent sequencing of the amplicons generated. Each repeat is assigned an 
alphanumeric number, the sequence of which can be analyzed using specialized 
mathematical models which, in reference to the central database, can map the relatedness 
between different spa sequences (Enright, Robinson et al. 2002; Strommenger, Kettlitz et al. 
2006). This analysis of the spa sequences is conducted using the specialised software 
package Ridom StaphType. The software consists of three modules: a sequence editor; a 
database; and a report generator module. For analysis, a spa sequence is uploaded onto the 
sequence editor where signature sequences flanking the variable region are detected by the 
software, thus allowing assignment of the corresponding spa type. The epidemiological data 
pertaining to that strain is added to the report generator module and the information is 
then saved onto a user database. The user database can subsequently be synchronised with 
a central database on the spa website, Spaserver (http://www.spaserver.ridom.de). 
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Synchronisation with the Spaserver allows for adoption of a common nomenclature and 
exchange of epidemiological data.  
By further classifying the spa types into spa complexes with respect to the similarity of the 
short tandem repeats, it is possible to use this technique both for short-term and long-term 
epidemiological studies (Ruppitsch, Indra et al. 2006). The application that allows 
assignment of spa types into clonal complexes is called ‘Based Upon Repeat Pattern (BURP)’ 
and is an additional application on the Ridom StaphType programme. A defined algorithm 
assigns spa types into complexes based on the relatedness of the repeats. Studies have 
shown very good correlation between spa complexes and MLST as well as PFGE complexes 
(Grundmann, Aires-de-Sousa et al. 2006; Mellmann, Weniger et al. 2008).  
Discordance between MLST and spa complexes can occur where a similar spa type can be 
mapped onto different MLST complexes. The ambiguity also applies to STs within the same 
CC where a spa type can exhibit different STs. This is attributed to convergent or parallel 
evolution of strains originally belonging to the same clonal lineage (Strommenger, Braulke 
et al. 2008). A combination of spa typing with another technique is therefore recommended 
especially in studies which require high levels of discrimination. 
1.4.1.4 SCCmec typing 
Knowledge of the SCCmec content of MRSA is important to an understanding of the 
epidemiology and evolutionary relationships of MRSA clones (Oliveira and de Lencastre 
2002). Multiplex PCR strategies have been developed for SCCmec typing (Oliveira and de 
Lencastre 2002; Milheirico, Oliveira et al. 2007; Kondo, Ito et al. 2007; Zhang, McClure et al. 
2009) where assignment of SCCmec type is based on the agarose gel electrophoresis profiles 
of the amplicons. Additionally, Oliveira and de Lencastre (2002) have developed a multiplex 
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PCR for the detection of SCCmec types I-IV, but as novel SCCmec types and subtypes were 
identified, these assays have been modified to accommodate the genetic diversity of the 
cassettes (Zhang, McClure et al. 2009; Milheirico, Oliveira et al. 2007).  
1.5 Overview of the distribution and population structure of S. aureus 
 
Application of the techniques described in the previous section has provided insight into the 
population structure and distribution of S. aureus. These techniques have revealed a 
population structure of S. aureus that is highly clonal when compared to other pathogenic 
bacteria such as Streptococcus pneumoniae, Neisseria meningitidis and Helicobacter pylori 
(Feil, Holmes et al. 2001; Feil, Cooper et al. 2003). The clonality of S. aureus is attributed to a 
low rate of recombination in the core genome which results in strains that are slow to 
diversify and are therefore highly related (Ruimy, Maiga et al. 2008). 
Studies comparing the global structure of MSSA with that of MRSA have shown that MSSA 
are more heterogenous, comprising strains which are genetically related to successful MRSA 
lineages as well as lineages which occur infrequently, if at all, in MRSA (Katayama, Robinson 
et al. 2005; de Sousa, Conceição et al. 2005; Vivoni, Diep et al. 2006; Hallin, Denis et al. 
2007; Goering, Shawar et al. 2008; Deurenberg and Stobberingh 2008; Ruimy, Maiga et al. 
2008; Baranovich, Zaraket et al. 2010; Wu, Wang et al. 2010; Breurec, Fall et al. 2011; 
Schaumburg, Kock et al. 2011).   One factor likely to have contributed to the heterogeneity 
in MSSA is time; on the evolutionary timescale MSSA are much older and therefore have 
had more time to diversify (Grundmann, Aanensen et al. 2010). 
A number of MSSA clones have been identified worldwide; however, some clones may be 
restricted to specific regions (Deurenberg and Stobberingh 2008; Grundmann, Aanensen et 
al. 2010). Our understanding of why some MSSA and MRSA clones are more prevalent in 
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local populations yet rare globally, is in its infancy. However, this phenomenon may be due 
to selection imposed by factors such as the environment and the host population,  as well as 
the competitive advantages of certain strains against other clones (Ruimy, Maiga et al. 2008; 
Fan, Shu et al. 2009). 
 The lack of heterogeneity in MRSA populations is attributed mainly to the acquisition of 
SCCmec by specific lineages, suggesting that acquisition and stability of SCCmec in S. aureus 
strains is highly dependent on the genetic backgrounds of the recipient MSSA isolates 
(Katayama, Robinson et al. 2005). Six major pandemic MRSA clones belonging to MLST CC1, 
CC5, CC8, CC22, CC30 and CC45 have been described (Enright, Robinson et al. 2002). Other 
lineages of MRSA have been identified but are less common (Monecke, Coombs et al. 2011). 
Undoubtedly, geographical spread of MRSA, following the acquisition of SCCmec, has played 
the major role in the world-wide prevalence of MRSA. Nevertheless, a report on the 
evolutionary history of MRSA ST5 (Nubel, Roumagnac et al. 2008) suggested that SCCmec 
acquisition events may be more frequent than was previously thought. In this context, the 
majority of MRSA ST5 investigated clustered according to geographic region, suggesting 
local acquisition of SCCmec (Nubel, Roumagnac et al. 2008). 
Similarly, Grundmann, et al. (2010) reported that MRSA populations tended to cluster 
geographically. In a study of 967 MRSA isolates, associated with invasive infections, from 
hospitals across Europe, 13 of the 15 major spa types identified showed restricted 
distribution (Grundmann, Aanensen et al. 2010). Furthermore, the study reported limited 
overlapping of no more than three clusters in the same region, suggesting that competitive 
advantages of existing strains over intruding or incoming clones may be a key factor in 
dissemination of clones into new environments. This is in agreement with Nubel, et al. 
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(2008) who suggested that MRSA clones are likely to predominate in environments for 
which they are best fitted.  
Indisputably, some clones, such as ST239-MRSA-III and ST22-MRSA-IV, have spread 
worldwide and have become predominant in new environments (Smith and Cook 2005; Cha, 
Moon et al. 2005; Aires-de-Sousa, Correia et al. 2008; Smyth, McDougal et al. 2010; 
Monecke, Coombs et al. 2011; Breurec, Fall et al. 2011). ST239-MRSA-III (CC8), also known 
as the Czech, Vienna, Hungarian, Portuguese or Brazillian clone, UK EMRSA-1, -4, -7, -9, -11, 
AUS-EMRSA-2, -3, Irish Phenotype III, Irish AR-01, -09, -15, -23, or Canadian MRSA-3, -6, is 
reported to be possibly the oldest pandemic clone and has been isolated from every 
continent.  It was reported to be the predominant MRSA clone in mainland Asia, accounting 
for 90% of hospital associated MRSA (HA-MRSA) (Chongtrakool, Ito et al. 2006; Feil, 
Nickerson et al. 2008) and was the second most prevalent strain in Western Australia 
between 2000 and 2004 (Coombs, Pearson et al. 2006).  
A study on the evolutionary history of ST239-MRSA-III, based on whole-genome sequencing 
of a global collection of 63 isolates, revealed three clades with this genetic background 
namely, South American, Asian and European clades. Clones and their variants from each of 
these clades have expanded intra-continentally (Harris, Feil et al. 2010). Evidence of 
intercontinental spread comes from reports of the identification and dominance of South 
American variants in Portugal between 1994 and 1997 (Aires-de-Sousa, Correia et al. 2008; 
Harris, Feil et al. 2010), while an Asian strain was responsible for a two year outbreak in a 
London hospital between 2002 and 2004 (Edgeworth, Yadegarfar et al. 2007).  Other 
examples include the close relatedness of isolates from USA with their counterparts in 
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Europe, and a similar relatedness between isolates from Egypt and Asian strains (Smyth, 
McDougal et al. 2010). 
A number of monikers, UK-EMRSA-15, Irish ARO6, Barnim Epidemic Strain, Spanish PFGE 
type E13 or Canadian MRSA-8 (Monecke, Coombs et al. 2011), have been assigned to ST22-
MRSA-IV which is also disseminated worldwide. Indeed this strain has displaced ST239-
MRSA-III in India (D'Souza, Rodrigues et al. 2010). Also, from the mid to late 1980s, ST239-
MRSA-III predominated in Irish hospitals, afterwhich, it was displaced by ST8-MRSA-IIA-E. 
Towards the end of the 1990s ST22-MRSA-IV emerged and by 2002 the strain was the 
predominant MRSA (Rossney and Keane 2002; Rossney, Lawrence et al. 2006). ST22-MRSA-
IV was first detected in both the Midlands and south-east of England in the early 1990s 
(Richardson and Reith 1993; Duckworth 1998; Johnson, Aucken et al. 2001; Moore and 
Lindsay 2002) but has since been reported to account for 85% of all MRSA bacteraemia 
cases across the UK (Monecke, Coombs et al. 2011). Further, in Western Australia, as a 
percentage of the annual number of persons colonised or infected with MRSA, the 
prevalence of ST22-MRSA-IV increased from 2% to 21% between 1997 and 2004 (Coombs, 
Pearson et al. 2006).  
Based on PFGE and spa typing, ST22-MRSA-IV is highly clonal, making it difficult to 
distinguish between strains (Goering, Shawar et al. 2008; Shore, Rossney et al. 2010). 
Carriage of virulence markers has been used to distinguish between ST22-MRSA-IV from 
different regions; for example, the Dublin clone is distinguished by carriage of the ACME-
locus while carriage of PVL and tst1 distinguishes the Indian clone (Monecke, Coombs et al. 
2011).  On the other hand, the Maltese clone can be distinguished by carriage of the fusidic 
acid resistance marker, Q6GD50 (Monecke, Coombs et al. 2011). Characterization of 
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virulence markers has identified cases of intra- and inter-continental transmission of ST22-
MRSA-IV clones; for example Indian clonal strains carrying the virulence marker, tst1, have 
also been identified in Abu Dhabi, Egypt, England (Monecke, Coombs et al. 2011) and USA 
(Wolter, Chatterjee et al. 2008). Shore, et al. (2010) reported an increased efficiency in the 
epidemiological characterisation of ST22-MRSA-IV in an endemic hospital setting by 
combining dru typing, which indexes the hypervariable dru region located between mecA 
and IS431 on the mec cassette, with spa and PFGE typing. The usefulness of dru typing in 
global epidemiological studies to distinguish between highly clonal strains such as ST22-
MRSA-IV, has not, to the best of the author’s knowledge, been reported.   
1.5.1 Health-care associated MRSA (HA- MRSA) 
MRSA was first identified in hospitals and has since been increasing in prevalence causing 
infections such as bacteraemia, pneumonia and surgical site infections, among others 
(Noble 1998). Studies have suggested an association of particular lineages of MRSA with the 
health-care setting; for example, the major clones of CC5, CC8, CC22, CC30, and CC45, are 
likely to be identified in connection with health-care predisposing factors such as recent 
hospitalization or invasive procedures such as implantation of foreign devices (Enright, 
Robinson et al. 2002; Deurenberg and Stobberingh 2008). Also, due to the less prudent use 
of antimicrobials, typical of health-care settings, health-care associated MRSA (HA-MRSA) 
are more likely to, but do not exclusively, carry SCCmec types I-III. These mec cassettes 
generally carry antibiotic resistance determinants, useful in a hospital setting, in addition to 
mecA (Enright, Robinson et al. 2002; Deurenberg and Stobberingh 2008; Monecke, Coombs 
et al. 2011).  
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1.5.2 Community-associated MRSA (CA-MRSA) 
CA-MRSA can cause minor infections such as skin and soft tissue infections. However, some 
CA-MRSA strains, such as MW2/USA400, have been reported to carry the Panton-Valentine 
leukocidin (PVL) toxin, a virulence factor often associated with rapidly progressive life-
threatening infections such as necrotising pneumonia occurring even among young healthy 
people (Boyle-Vavra and Daum 2007; Monecke, Coombs et al. 2011). 
It has been suggested that the emergence of CA-MRSA coincided with the emergence of the 
smaller SCCmec types, IV and V, which had been described mostly in MRSA identified 
outside of health care settings (Grundmann, Aires-de-Sousa et al. 2006; Monecke, Coombs 
et al. 2011). The literature indicates that MRSA carrying these SCCmec types are now 
present in hospitals in many countries, blurring the distinction between CA-MRSA and HA-
MRSA (Moore and Lindsay 2002; Huang, Tseng et al. 2007; Deurenberg and Stobberingh 
2008; Reinert, McCulloch et al. 2008; Basset, Senn et al. 2010; Jansen van Rensburg, Eliya 
Madikane et al. 2011; Chen, Wang et al. 2010).  
1.6 MRSA in South Africa 
Prevalence rates of MRSA circulating in South African hospitals vary throughout the country 
with Gauteng and Kwa-Zulu Natal (KZN) provinces reporting rates of 23% (Perovic, Koornhof 
et al. 2006) and 27% (Shittu and Lin 2006), respectively. Current information from three 
Cape Town hospitals suggests MRSA prevalence rates ranging between 26% and 35% for S. 
aureus isolated from blood cultures between January and December 2009 (NHLS Public 
Sector Susceptibility Data, Dr Colleen Bamford).  
There have been few studies on the molecular epidemiology of S. aureus in South Africa 
(Shittu, Nubel et al. 2009; Makgotlho, Kock et al. 2009; Moodley, Oosthuysen et al. 2010; 
Jansen van Rensburg, Eliya Madikane et al. 2011). In their study, Moodley, et al. (2010) 
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characterized 320 MRSA isolates, collected between August 2005 and November 2006, from 
15 state and eight private diagnostic microbiology laboratories, to describe the population 
structure of MRSA in the nine provinces South Africa.  The study reported five major clonal 
types, PFGE A-SCCmec I-spaCC5-ST5 (n=21), PFGE D-SCCmec III-spaCC12-ST239 (n=67), PFGE 
F-SCCmec IV-spaCC64-ST612 (n=20), PFGE K-SCCmec IV-spaCC64-ST612 (n=61), and PFGE T-
SCCmec II-spaCC12-ST36 (n=76), which were distributed throughout the country (Fig 1.5).  
 
 
Figure 1.5: The distribution and frequencies of the five major MRSA clonal types identified in the study by 
Moodley, et al. (2010), in South Africa. L, Limpopo; GP, Gauteng province; MPN, Mpumalanga; NW, North 
West; FS, Free State; KZN, Kwa-Zulu Natal; EC, Eastern Cape; NC, Northern Cape; WP, Western Province.  
Adapted from Moodley, et al. (2010). 
 
As the number of isolates from the regional centres in each of the provinces is unknown, it 
is difficult to draw conclusions about geographical clustering or restriction of clones. 
Nevertheless, based on the data presented in Fig 1.5, PFGE D-SCCmec III-spaCC12-ST239 
may be more prevalent in provinces north of the Western Province and the Eastern Cape. 
Although ST612-MRSA-IV was isolated from all provinces, PFGE F-SCCmec IV-spaCC64-ST612 
was not identified in three northern provinces: Gauteng, North West and Limpopo 
(Moodley, Oosthuysen et al. 2010). While this is the first study that describes the clonal 
A, PFGE A-SCCmec I-spaCC5-ST5 (n=21) 
D, PFGE D-SCCmec III-spaCC12-ST239 (n=67) 
F, PFGE F-SCCmec IV-spaCC64-ST612 (n= 20) 
K, PFGE K-SCCmec IV-spaCC64-ST612 (n=61) 
T, PFGE T-SCCmecII-spaCC12-ST36 (n=76) 
NC 
GP 
MPN 
L 
NW 
FS 
KZN 
EC 
WP 
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types of MRSA throughout South Africa, other studies describing MRSA from individual 
provinces have been reported. For instance, Shittu, et al. (2009) identified spaCC12-ST239-
SCCmec III in KZN between March 2001 and August 2003, a finding subsequently 
corroborated by Moodley, et al.  In Shittu’s study, spaCC64-ST1338-SCCmec IV and spaCC64-
ST1173-SCCmec IV, single and double locus variants of spaCC64-ST612-SCCmec IV, together 
constituted the dominant cluster. 
In a recent study by Jansen van Rensburg, et al. (2011) in which 100 MRSA isolates, 
collected, froma variety of infections, between January 2007 and December 2008 from five 
Cape Town hospitals, were characterized, ST612-MRSA-IV was identified as the 
predominant MRSA followed by ST5-MRSA-I and then ST36-MRSA-II. Interestingly, in 
agreement with the findings of Moodley, et al. (2010), ST239-MRSA-III was not common in 
Cape Town hospitals (Fig 1.6) (Jansen van Rensburg, Eliya Madikane et al. 2011). 
 
MLST of 100 MRSA isolates  from 
five Cape Town hospitals
ST612; CC8 (SCCmecIV)
ST5; CC5 (SCCmecI)
ST36; CC30 (SCCmecII)
ST239; CC8 (SCCmecIII)
ST72; CC8  (SCCmecNT)
ST22; CC22 (SCCmecIV)
ST650; CC5 (SCCmecIV)
 
Figure 1.6: MLSTs of 100 MRSA. The isolates were collected between January 2007 and December 2008 from 
five Cape Town hospitals (Jansen van Rensburg, Eliya Madikane et al. 2011). 
NT, not typable. 
 
The high frequency of ST612-MRSA-IV across South Africa (Moodley, Oosthuysen et al. 
2010; Jansen van Rensburg, Eliya Madikane et al. 2011) as well as the high prevalence of its 
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variants, spaCC64-ST1173-SCCmec IV and spaCC64-ST1338-SCCmec IV, in KZN (Shittu, Nubel 
et al. 2009) make it possible to suggest that this clone may be best fitted to South Africa. To 
date, Australia is the only other country that has reported ST612-MRSA-IV, and then only 
two isolates. The studies carried out by Jansen van Rensburg, et al which included molecular 
characterisation of the two Australian isolates led to the suggestion that ST612-MRSA-IVd 
may have arisen locally (Jansen van Rensburg, Eliya Madikane et al. 2011).   
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1.7 The aims and objectives of the study 
The aims of the study were: 1) to determine whether ST612-MSSA was present in hospitals 
in Cape Town and 2) to characterize any ST612-MSSA identified.  
The objectives of the study are: 
 To screen a small sample collection of MSSA isolates, collected from four hospitals in 
Cape Town between February 2007 and December 2008, using spa typing and MLST 
to determine the presence of MSSA ST612. 
 
 To describe ST612-MSSA isolates identified. 
 To understand the relatedness of ST612-MSSA isolates to their MRSA counterparts. 
 To determine whether the presence of SCCmec imposes a fitness cost on ST612-
MRSA-IV isolates.  
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CHAPTER 2 
___________________________________________________________________________ 
 
 
 
 
 
 
Screening of 19 MSSA isolates from Cape Town 
hospitals using spa typing and MLST for the 
identification of ST612-MSSA. 
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2.1 Abstract 
 
A previous study characterizing 100 MRSA isolates, collected between January 2007 and 
December 2008 from five Cape Town hospitals, identified ST612-MRSA-IV as the 
predominant MRSA. Interestingly, Australia is the only other country which has reported 
this genetic background and then for only two isolates. To the best of the author’s 
knowledge there have been no reports of the identification of ST612-MSSA. Nineteen MSSA 
isolates, which were collected during the same period, and from four of the hospitals in 
Cape Town, as the previously characterized MRSA isolates, were screened for the presence 
of ST612-MSSA.    
Initially, spa typing was used to detect spa types associated with ST612-MRSA-IV. Based on 
these results, MLST was conducted to determine the STs of the relevant MSSA isolates.  
A total of 10 spa types were detected among the 19 isolates. spa type t891, associated with 
ST22, was detected in nine isolates but only one isolate had a spa type (t064) associated 
with ST612. MLST defined these genetic backgrounds for the respective isolates. This study, 
therefore, reports the first identification of ST612-MSSA. 
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2.2 Introduction 
 
A previous study which characterized 100 MRSA isolates, collected over a 24 month period 
between January 2007 and December 2008 from five Cape Town hospitals, identified ST612-
MRSA-IV as the predominant strain.  To date, Australia is the only other country which has 
reported clinical MRSA with this genetic background, and then for only two isolates (Jansen 
van Rensburg, Eliya Madikane et al. 2011). Subsequently ST612-MRSA was isolated from 
horses in Australia (Axon, Carrick et al. 2011). However, the SCCmec type (SCCmec IVd) is 
different from that of t he equine isolates (SCCmec IVa) (Axon, Carrick et al. 2011; Jansen 
van Rensburg, Whitelaw et al. 2012) 
Recent studies have suggested the geographic restriction of some MRSA populations. It is 
supposed that S.aureus strains are likely to emerge and predominate in environments for 
which they are best fitted (Nubel, Roumagnac et al. 2008). In this context, it was suggested 
that ST612-MRSA-IV originated locally and expanded following the acquisition of SCCmec by 
a methicillin susceptible ST612 or a closely related strain (Jansen van Rensburg, Eliya 
Madikane et al. 2011). 
The best strategy to determine whether ST612-MRSA-IV arose locally would have been to 
analyse a longitudinal collection of MSSA isolates that preceded the emergence of ST612-
MRSA-IV; regrettably, no such collection was available.  However, MSSA isolates 
contemporaneous with the previously characterized local MRSA were available. Although 
not ideal, considering the possibility that ST612-MRSA-IV may have emerged some time ago, 
these MSSA isolates were screened for the presence of ST612 strains.   
A number of studies to determine the relatedness between the genetic backgrounds of 
MRSA and MSSA populations from the same settings have been carried out. A study 
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involving 450 hospitals in 26 European countries identified geographical clustering of MRSA 
spa types whereas the spa types in MSSA were more geographically diverse than their 
MRSA counterparts (Grundmann, Aanensen et al. 2010). Studies involving 
contemporaneous MRSA and MSSA populations from the same settings have also been 
carried out (de Sousa, Conceição et al. 2005; Vivoni, Diep et al. 2006; Hallin, Denis et al. 
2007; Goering, Shawar et al. 2008; Baranovich, Zaraket et al. 2010; Wu, Wang et al. 2010; 
Breurec, Fall et al. 2011). Most of these studies have reported some incongruence between 
the genetic backgrounds of the predominant MRSA and MSSA isolates. The study by 
Baranovich, et al. (2010), which compared the genetic relatedness between 30 MRSA and 33 
MSSA isolates collected between August 2006 and April 2007 in four hospitals in Russia, 
reported ST239 as predominant in and exclusive to the MRSA, while the dominant MSSA 
was ST121 which was also exclusive to the MSSA. This is not surprising as ST239 has only 
been identified in MRSA populations while ST121 is extremely rare among MRSA 
populations (Smyth, McDougal et al. 2010; Monecke, Coombs et al. 2011). The same results 
were reported in a study by Breurec, et al. (2011) where the genetic relatedness between 99 
MRSA and 456 MSSA isolates, collected between January 2007 and March 2008 from seven 
hospitals in five African countries (Madagascar, Morocco, Senegal, Niger and Cameroon), 
was investigated. Similarly, ST239 was identified as one of the predominant MRSA which 
also included ST88 and ST5; while ST121, ST15 and ST152 were the leading MSSA. Only 7% 
of the MSSA had genetic backgrounds corresponding to the major MRSA clones identified in 
the study (Breurec, Fall et al. 2011). 
With few exceptions, the study by de Sousa, et al. (2005) supports the premise that global 
spread of MRSA has played the more important role in the expansion of MRSA populations. 
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A comparison of the STs of MSSA and MRSA, coincident with the emergence of dominant 
MRSA clones ST247 (1992-1993), ST239 (1995) and ST22 (2001), obtained from three 
Portuguese hospitals and the community served by these hospitals, did not identify or rarely 
detected  MSSA isolates corresponding to these genetic backgrounds. Nevertheless there 
was some overlap between the backgrounds of MSSA and MRSA; ST5, which was identified 
as one of the dominant MSSA, was also identified among the MRSA (ST5-MRSA-IV/ 
Paediatric clone). Although it was not a major MRSA clone during the period of 
investigation, as ST5-MRSA-IV was first described in a paediatric Portuguese hospital (Sa-
Leao, Santos Sanches et al. 1999), de Sousa, et al. (2005) suggested that the clone may have 
emerged within Portugal following acquisition of SCCmec IV by ST5-MSSA.    
In contrast, a study by Hallin, et al. (2007), which involved the molecular characterisation of 
contemporaneous collections of 103 MSSA and 511 MRSA strains from a national survey of 
patients admitted to 112 Belgian hospitals in 2003, identified predominant MSSA lineages 
which were also common among the successful MRSA clones in the population. The most 
common MSSA lineages identified were ST5 and ST45 accounting for 18% and 14% of the 
isolates, respectively. ST45 was the most common genetic background (49%) among the 
MRSA populations while ST5-MRSA was third, accounting for 10% of the MRSA.  Further 
characterisation of the MSSA and MRSA isolates using PFGE identified common PFGE types 
between the populations for both ST5 and ST45 which led the authors to suggest that the 
MRSA clones may have emerged in Belgium. 
In this context, the objective of the work described in this chapter was to determine 
whether ST612 was present in MSSA collected simultaneously with the previously 
characterized local MRSA. In the study of ST612-MRSA-IV, four spa types t064, t1443, t1257, 
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and t2196 were identified in the 44 ST612-MRSA-IV isolates identified (Jansen van Rensburg, 
Eliya Madikane et al. 2011). In the current study, spa typing was used for the initial 
molecular characterisation of the MSSA isolates and, based on the results, MLST was carried 
out to determine the STs of relevant isolates.  
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2.3 Materials and Methods 
2.3.1 MSSA isolates included in the study 
 
The MRSA which were characterized by Jansen van Rensburg, et al. (2011) in the previous 
project and the MSSA characterized in the current project are contemporaneous collections. 
The MRSA collections were obtained from paediatric and adult patients from five hospitals 
in Cape Town, South Africa, namely Groote Schuur hospital (GSH); Red Cross Children’s 
hospital (RCCH); Mowbray Maternity hospital (MMH); UCT Private Hospital (UCTPH) and 
Victoria hospital (VH) between January 2007 and December 2008.  The MSSA samples were 
collected from the same hospitals with the exception of VH and between February 2007 and 
December 2008. A single colony for each sample was sub-cultured in broth then stored at -
80°C in 50% glycerol. 
Antibiotic susceptibility testing was carried out at the National Health Laboratories Service 
laboratory (NHLS), GSH, using disc diffusion method or the VITEK 2 system (Card #) and the 
results re presented in Table 2.1. Zone sizes or VITEK 2 MIC results were interpreted using 
the Clinical Laboratory Standards Institute (CLSI) breakpoints, as well as the Advanced 
Expert System of the VITEK 2.  
PFGE of the MRSA isolates (Jansen van Rensburg, Eliya Madikane et al. 2011) segregated 
ST612-MRSA-IV strains into two clusters, D and E and four singletons. Antimicrobial 
susceptibility patterns of representative strains from each cluster as well as those of the 
singletons were used as guidelines in the selection of the MSSA isolates in the current study 
(Table 2.1). 
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Table 2.1: Antibiotic resistance patterns of ST612-MRSA-IV strains. 
 
 
PFGE cluster*  Representative strains 
Antibiogram  
P Clo E Cli Rif Co Ci G F V L 
D D4 R R R R R R S R S S S 
E E3 R R S S R R R R S S S 
E8 R R R R R R R R S S S 
Singleton S5 R R S S R R S R S S S 
* (Jansen van Rensburg, Eliya Madikane et al. 2011). 
 
P, penicillin; Clo, cloxacillin; E, erythromycin; Cli, clindamycin; Rif, rifampicin; Co, co-trimoxazole; Ci, 
ciprofloxazin; G, gentamicin; F, fusidic acid; V, vancomycin; L, linezolid. R, resistant; S, susceptible. 
 
Nineteen MSSA isolates were selected for the investigation (Table 2.2), 14 (MS1-MS14) of 
which had antibiotic susceptibility profiles, with the exception of resistance to fusidic acid, 
similar to those of ST612-MRSA-IV (Table 2.1). An additional five MSSA strains (MS15-MS19) 
were included so as to be inclusive of the susceptibility profiles of the MSSA collection.   
Table 2.2: MSSA isolates selected for strain typing and their corresponding antibiograms  
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P, penicillin; Clo, cloxacillin; E, erythromycin; Cli, clindamycin; Rif, rifampicin; Co, co-trimoxazole; Ci, 
ciprofloxazin; G, gentamicin; F, fusidic acid; V, vancomycin; L, linezolid. R, resistant; S, susceptible; NT, not 
tested. 
 
 MSSA isolates Date of isolation 
                                                   Antibiogram 
P Clo E Cli Rif Co Ci G F V L 
MS1 10.02.2007 R S S R S R R S S S NT 
MS2 26.02.2007 R S S S S R S R S S NT 
MS3 26.02.2007 R S S S S R S R S S NT 
MS4 11.06.2007 R S R R S R S S S S NT 
MS5 12.06.2007 S S R R S R S R R S S 
MS6 12.12.2007 R S S S R R S S S S S 
MS7 30.12.2007 R S S S S R S R S S S 
MS8 19.02.2008 R S S S S R S R S S S 
MS9 19.02.2008 S S R R S S S R R S S 
MS10 07.04.2008 R S S S S R S R S S S 
MS11 27.04.2008 R S S S S R S R S S S 
MS12 22.08.2008 R S S S S R S R S S S 
MS13 01.09.2008 R S S S S R S R S S S 
MS14 14.12.2008 R S R R R R S R S S S 
MS15 05.07.2007 R S S S S S S R S S NT 
MS16 16.01.2008 S S S S S S S S S S S 
MS17 22.02.2008 R S S S R S S S S S NT 
MS18 28.02.2008 R S R S S S S S S S NT 
MS19 10.03.2008 R S S S S S S R S S S 
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2.3.2  Extraction of whole-genomic DNA  
Each MSSA strain was individually cultured overnight on a boiled blood agar plate (Green 
point NHLS laboratories, Cape Town) at 37°C in preparation for extraction of DNA (Hal S. 
Larsen 1995). Extraction of DNA from the isolates was carried out using the QIAamp DNA 
mini and Blood mini kit (Qiagen, South Africa). The extraction process included pre-
treatment of the isolates with 25 µg/ml lysostaphin, an antistaphylococcal lytic enzyme, in 
order to lyse the cells.  After cell lysis, the DNA was then isolated from the cell debris, RNA 
and proteins according to the instructions from the kit. This process starts with the addition 
of 20 µl proteinase K provided in the kit, which is a broad spectrum proteolytic enzyme 
aimed at digestion of proteins from the cell lysate that may include nucleases that may 
otherwise degrade the DNA. The subsequent steps included treatment of the cell lysate with 
the buffers included in the kit; precipitation of the DNA following the addition of absolute 
ethanol (EtOH); adhesion of the genomic DNA onto a silica membrane in the QIAmp spin 
columns provided in the kit; and the subsequent elution of the DNA using the elution buffer 
also provided in the kit. Centrifugation and vortexing were carried out where stipulated in 
the protocol.  The genomic DNA was suspended in 50 µl of the elution buffer.  
To determine the integrity of the genomic DNA, 10 µl of the suspension was 
electrophoresed on a 1% (w/v) agarose gel with 5 µl/100 ml (v/v) ethidium bromide (EtBr) 
(10 mg/ml) at 90V for 60 minutes and visualised under UV light.  
The genomic DNA was quantified using the Nanodrop spectrophotometer, ND-1000 UV/Vis 
(Thermo Fisher Scientific Inc, Delaware, USA).The remaining genomic DNA suspensions were 
stored at 4°C until further use.  
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2.3.3 Molecular typing  
2.3.3.1 spa typing 
This technique involves the amplification and subsequent sequencing of an internal 
fragment of the spa hypervariable region for each of the isolates. The PCR protocol included 
the primers, spa-1113f (5’-TAA AGA CGA TCC TTC GGT GAG C-3’) and spa-1514r (5’-CAG CAG 
TAG TGC CGT TTG CTT-3’), described by Strommenger, et al. (2008) to produce amplicons of 
variable sizes depending on the number and type of the repeats. All primers used in the 
current and subsequent studies were synthesised at the DNA synthesis laboratory, 
Department of Molecular and Cellular Biology, University of Cape Town, South Africa. 
The PCR assay consisted of 1X PCR buffer; 1.5 mM MgCl2; 400 µM dNTPs; 1.25 U 
SuperTherm Taq polymerase (all four items were purchased from Southern Cross 
Biotechnology, Cape Town, South Africa); 0.2 µM of each primer; and 5 µl of the genomic 
DNA extracts to a final volume of 50 µl. The PCR was carried out on the 2720 thermal cycler 
(Applied Biosystems, South Africa) with the cycling conditions as follows: initial denaturation 
at 80°C for 5 min followed by 35 cycles of denaturation at 94°C for 45 s, annealing at 60°C 
for 45 s and extension at 72°C for 90 s with a final extension at 72°C for 10 min.  
The products were electrophoresed on a 2% (w/v) agarose gel with 5 µl/100 ml (v/v) EtBr 
(10 mg/ml) at 80V for 95 min and then viewed under UV light. The MRSA strain COL 
(generously provided by Prof. Hermínia de Lencastre, Professor and Head, Laboratório de 
Genética Molecular, Instituto de Tecnologia Química e Biológica, Oeiras, Portugal) was used 
as a positive control for the amplification process but was not included for further 
experiments.  
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A MinElute gel extraction kit (Qiagen) was used to purify the PCR products following the 
excision of the respective bands after gel electrophoresis (60V for 3 h) of the PCR products. 
The purified PCR products were then sent for automated sequencing at the Central 
Analytical Facility in Stellenbosch. The same primer pairs used for PCR were also used for 
sequencing.  
Sequence analysis was carried out using the Ridom StaphType software package version 1.4 
(Ridom GmbH, Wϋrzburg, Germany). This process was preceded by an initial analysis of the 
forward and reverse sequences using the sequence analyser, BioEdit v7.0.5 (Ibis Biosciences, 
California, USA), to ensure that the sequences did not contain mismatched bases and that 
both contained the spa signature sequences provided on the SpaServer 
(http://spaserver.ridom.de) which are short sequences which flank the spa repeats. Both 
the reverse and forward sequences were then uploaded onto the Ridom StaphType 
programme and then subsequently assigned the corresponding spa type (Harmsen, Claus et 
al. 2003). 
2.3.3.2 Multilocus sequence typing (MLST)  
 MSSA isolates with spa types associated with ST612-MRSA-IV were characterized further 
using MLST, a technique that involved the amplification of internal fragments of seven loci, 
arcC, aroE, glpF, gmk, pta, tpi and yqiL, described in Chapter 1, and the subsequent 
sequencing of the amplicons. Individual PCR assays were performed using previously 
described primer pairs and PCR protocols (Table 2.3) (Enright, Day et al. 2000).  All of the 
reagents used in the assay, with the exception of the primers, were purchased from 
Southern Cross Biotechnology.  
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Table 2.3: PCR primers and PCR protocols for MLST of the MSSA isolates  
 
Gene Primer pairs
1 
Primer sequences (5’-3’) Components in individual 
PCR assays 
PCR Amplification 
arcC arcC UP 
arcC DN 
TTGATTCACCAGCGCGTATTGTC 1X PCR buffer; 1.5 mM 
MgCl2; 
200 µM dNTPs; 1U 
SuperTherm Taq 
polymerase;  
0.5 µM of each primer; 
and 100 ng of the 
genomic DNA. 
Initial denaturation at 
95°C for 5 min. 30 
cycles of 
denaturation at 95°C 
for 1 min; annealing 
at 55°C for 1 min; 
extension at 72°C for 
1 min. Final extension 
at 72°C for 5 min. 
AGGTATCTGCTTCAATCAGCG 
aroE aroE UP 
aroE DN 
ATCGGAAATCCTATTTCACATTC 
GGTGTTGTATTAATAACGATATC 
glpF glpF UP 
glpF DN 
CTAGGAACTGCAATCTTAATCC 
TGGTAAAATCGCATGTCCAATTC 
gmk gmk UP 
gmk DN 
ATCGTTTTATCGGGACCATC 
TCATTAACTACAACGTAATCGTA 
pta pta UP 
pta DN 
GTTAAAATCGTATTACCTGAAGG 
GACCCTTTTGTTGAAAAGCTTAA 
yqil yqil UP 
yqil DN 
CAGCATACAGGACACCTATTGGC 
CGTTGAGGAATCGATACTGGAAC 
tpi tpi UP 
tpi DN 
TCGTTCATTCTGAACGTCGTGAA Same as above but 
increased dNTP 
concentration (400 µM) TTTGCACCTTCTAACAATTGTAC 
1
As described by Enright, Day et al. (2000). 
 
The PCR products were separated by gel electrophoresis and purified [2.3.3.1]. The purified 
PCR products were sequenced at the Central Analytical Facility in Stellenbosch. The same 
primers used for PCR (Table 2.3) were also used for sequencing.  
Sequence analysis began with the alignment of the generated sequences to a reference 
sequence, provided on the MLST website (http://saureus.mlst.net/), for each of the genes 
using the sequence alignment editor and analysis program, BioEdit v7.0.5. The purpose of 
the alignment to a reference sequence was to ensure that the sequence is the correct 
length for the respective internal fragment of the gene. The edited sequence was then 
uploaded onto the MLST website. On the website, each sequence was synchronised with a 
global database and subsequently assigned an appropriate allelic number. The seven allelic 
numbers for the seven loci then generated an allelic profile which defined the sequence 
type (ST) for the particular isolate (Enright, Day et al. 2000).  
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2.4  RESULTS 
2.4.1  spa typing 
 
 
 
Figure 2.1: Gel electrophoresis of the spa amplicons for the 19 MSSA isolates. Lanes 1-5, MS1-MS5; Lane 6, 
MS15; Lanes 7-8, MS6-MS7; Lane 9, MS16; Lanes 10-11, MS8-MS9; Lanes 12-14, MS17-MS19; Lanes 15-19, 
MS10-MS14. MRSA COL was used as a positive control for the reaction. H2O, the water control, containing no 
DNA, was used as a negative control for the reaction. H4, HyperLadder IV
TM
 molecular weight marker (Celtic 
Molecular Diagnostics, Cape Town, South Africa). 
 
 
A product of the expected size (~380bp) was obtained from the MRSA COL strain as well as 
ampicons of varying sizes from each of the 19 MSSA isolates (Figure 2.1). Following the 
extraction, purification and sequencing of the amplicons, the data were analysed using the 
Ridom StaphType [2.3.3.1] to assign the corresponding spa types.  
Of the 19 isolates, only one had a spa type (t064) which was identified in ST612-MRSA-IV 
(Jansen van Rensburg, Eliya Madikane et al. 2011) (Table 2.4). For the remaining isolates, 
the association of each spa type to a ST was established on the MLST mapping technique 
described on the SpaServer (http://spaserver.ridom.de). One isolate had a novel spa 
sequence (26-23-25-17-25-28) and could therefore not be associated with a ST. 
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Interestingly, nine of the isolates had a spa type, t891, associated with ST22 (Table 2.4). A 
variety of spa types were identified in the remaining MSSA strains (Table 2.4). 
Table 2.4: spa types of the 19 MSSA isolates and the associated STs. 
 MSSA isolate Date of isolation 
                                 Antibiogram   
P Clo E Cli Rif Co Ci G F V L spa type Associated ST* 
MS1 10.02.2007 R S S R S R R S S S NT t345 ST5 
MS2 26.02.2007 R S S S S R S R S S NT t891 ST22 
MS3 26.02.2007 R S S S S R S R S S NT novel unknown 
MS4 11.06.2007 R S R R S R S S S S NT t1835 ST9 
MS5 12.06.2007 S S R R S R S R R S S t1805 ST45 
MS6 12.12.2007 R S S S R R S S S S S t891 ST22 
MS7 30.12.2007 R S S S S R S R S S S t891 ST22 
MS8 19.02.2008 R S S S S R S R S S S t891 ST22 
MS9 19.02.2008 S S R R S S S R R S S t1805 ST45 
MS10 07.04.2008 R S S S S R S R S S S t891 ST22 
MS11 27.04.2008 R S S S S R S R S S S t891 ST22 
MS12 22.08.2008 R S S S S R S R S S S t891 ST22 
MS13 01.09.2008 R S S S S R S R S S S t891 ST22 
MS14 14.12.2008 R S R R R R S R S S S t064 ST612 
MS15 05.07.2007 R S S S S S S R S S NT t891 ST22 
MS16 16.01.2008 S S S S S S S S S S S t127 ST1 
MS17 22.02.2008 R S S S R S S S S S NT t2360 ST6 
MS18 28.02.2008 R S R S S S S S S S NT t888 ST12 
MS19 10.03.2008 R S S S S S S R S S S t071 ST5 
*Identified using the MLST mapping application on the SpaServer (http://spaserver.ridom.de). 
 
P, penicillin; Clo, cloxacillin; E, erythromycin; Cli, clindamycin; Rif, rifampicin; Co, co-trimoxazole; Ci, 
ciprofloxazin; G, gentamicin; F, fusidic acid; V, vancomycin; L, linezolid. R, resistant; S, susceptible; NT, not 
tested. 
 
2.4.2 MLST 
 
The ST of MS14, which was spa t064, previously shown to be associated with ST612-MRSA-
IV, was determined. Although not an objective of this work, the STs of the nine isolates 
associated with ST22 were also determined. In addition, the ST of the isolate with the novel 
spa sequence was also defined. 
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Following amplification and subsequent agarose gel electrophoresis of the amplicons 
[2.3.3.2] as shown in Fig 2.2, the sequencing data obtained from purified products [2.3.3.2] 
were analysed [2.3.3.2].  
 
 
 
Figure 2.2: Gel electrophoresis of arcC, aroE, glfP, gmk, pta, tpi and yqiL  amplicons for MLST of one of the 
MSSA isolates. H2O, the water control, containing no DNA, used as a negative control for the reaction. H4, 
HyperLadder IV
TM
 molecular weight marker (Celtic Molecular Diagnostics, Cape Town, South Africa). 
 
 
The strain that was spa t064 was defined as ST612, while the strains which were spa t891 
were defined as ST22. Additionally, the strain that had the novel spa sequence was also 
defined as ST22. 
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2.5  Discussion  
ST612-MRSA-IV was predominant among a collection of 100 MRSA isolates, accumulated 
over a 24 month period between 2007 and December 2008, from paediatric and adult 
patients from five hospitals in Cape Town (Jansen van Rensburg, Eliya Madikane et al. 2011). 
To date, Australia is the only other country that has reported ST612-MRSA-IV, and then only 
two isolates (Jansen van Rensburg, Whitelaw et al. 2012). Molecular characterisation of the 
local strains, including two isolates previously isolated in South Africa (Goering, Shawar et al. 
2008), and the two Australian isolates led to the suggestion that ST612-MRSA-IV may have 
arisen locally (Jansen van Rensburg, Eliya Madikane et al. 2011).   
Based on studies which have demonstrated congruency in the genetic relatedness between 
contemporaneous MSSA and MRSA populations from the same setting as described in the 
introduction of this chapter, the objective of the current study was to determine if ST612-
MSSA was present among MSSA isolates collected simultaneously with the previously 
characterized MRSA.  
Only one of the 19 isolates had a spa type (t064) associated with ST612. MLST identified this 
background for the strain. This strain was resistant to a number of antibiotics including 
rifampicin and co-trimoxazole, similar to the profile of D4 (Table 2.1). It was suggested by 
Jansen van Rensburg, et al. (2011) that the frequent use of rifampicin and co-trimoxazole in 
the treatment of Mycobaterium tuberculosis and Pneumocystis infections in HIV infected 
individuals in South Africa may have selected for the emergence of S. aureus resistant to 
these antibiotics.  That ST612-MSSA strain also demonstrated resistance to the same 
antibiotics is interesting and raised the question as to whether MSSA isolates with this 
genetic background may also be best fitted to the local environment. 
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MLST defined 10 MSSA as ST22; the same spa type (t891) was detected in nine of the 
isolates while a novel spa sequence was detected in the remaining isolate. This is not the 
first report of ST22-MSSA from South Africa; out of 70 MSSA isolates collected between 
2004 and 2005 and characterized by Goering, et al. (2008) during five global clinical trials of 
the antibiotic, repatamulin, 13 isolates with this genetic background were identified. 
Interestingly, only one ST22-MRSA isolate was identified in the 100 MRSA isolates 
characterized by Jansen van Rensburg, et al. (2011). Also, in a study that characterized 320 
MRSA, collected between August 2005 and November 2006 at 15 state and eight private 
diagnostic microbiology laboratories in the nine provinces in South Africa, only four ST22-
MRSA isolates were identified, thus suggesting the scarcity of this genetic background 
among MRSA in the local environment (Moodley, Oosthuys n et al. 2010).  
In contrast, ST22-MRSA-IV, which corresponds to the endemic UK-EMRSA 15 strain, is one of 
the major international clones of HA-MRSA prevalent in Europe and some parts of South 
East Asia (Deurenberg and Stobberingh 2008; D'Souza, Rodrigues et al. 2010). The scarcity of 
ST22-MRSA-IV in South Africa could suggest a recent emergence of this ST either through 
local acquisition of SCCmec into ST22-MSSA isolates or a recent importation of the resistant 
strain.  
A variety of spa types was identified in the remaining MSSA isolates which were equally 
associated with a variety of STs. Two of the isolates carried spa types t071 and t345, which 
are both associated with ST5. Interestingly, ST5-MRSA-I was the second most prevalent 
clone in the contemporaneous MRSA collection. Jansen van Rensburg, et al. (2011) 
suggested a possible local origin of ST5-MRSA based on the theory of multiple acquisitions 
of SCCmec into this genetic background (Nubel, Roumagnac et al. 2008). While the 
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identification of MSSA isolates associated with ST5 in the same hospitals as ST5-MRSA–I, 
albeit with different spa types, does not unequivocally prove that ST5-MRSA arose locally, it 
does provide evidence of a presence of a suitable MSSA background for such an event. 
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CHAPTER 3 
___________________________________________________________________________ 
 
 
 
 
 
 
An investigation of the ST612-MSSA isolate recovered 
from strain typing of 19 MSSA isolates from five Cape 
Town hospitals  
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3.1 Abstract 
MS14 was identified as ST612-MSSA-t064 as described in the previous chapter. MS14 was 
resistant to penicillin, erythromycin, clindamycin, rifampicin, co-trimoxazole and 
gentamicin; and was sensitive to cloxacillin, ciprofloxacin, fusidic acid, vancomycin and 
linezolid.  This antibiotic susceptibility pattern was similar to that seen in ST612-MRSA-IV 
isolated from hospitals in Cape Town.  
Recent studies have identified remnants of SCCmec in multi-drug resistant MSSA from 
hospitals, suggesting partial loss of these elements from the corresponding MRSA. PCR to 
detect remnants of SCCmec in MS14 was conducted; subsequent sequencing of the 
amplicons identified the dcs region of SCCmec. Additional PCR assays indicated that this 
region is located 1.7kb upstream of the orfX region.   
To better understand the relatedness of MS14 to the ST612-MRSA-IV strains, the nucleotide 
sequence of the internal fragment of the rifampicin-resistance determining region of the 
rpoB gene in MS14 was compared with the corresponding region in ST612-MRSA-IV. The 
amino acid substitutions (H481N, I527M) previously identified in ST612-MRSA-IV were also 
present in the rpoB in MS14.  
These data support the suggestion that MS14 resulted from a partial loss of SCCmec from a 
ST612-MRSA strain.  
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3.2 Introduction 
 
MS14, isolated from a patient with septic arthritis at the Red Cross Children’s Hospital in 
December 2008, was identified as ST612-MSSA-t064 as described in the previous chapter. 
MS14 was resistant to penicillin, erythromycin, clindamycin, rifampicin, co-trimoxazole and 
gentamicin; and was sensitive to cloxacillin, ciprofloxacin, fusidic acid, vancomycin and 
linezolid.  This antibiotic susceptibility pattern was similar to that seen in ST612-MRSA-IV 
isolates (Jansen van Rensburg, Eliya Madikane et al. 2011). Recently a number of studies 
have shown that MSSA, particularly multi-drug resistant strains, defined as strains resistant 
to at least one agent in three classes of antimicrobials (Magiorakos, Srinivasan et al. (2011), 
frequently contain remnants of SCCmec, suggesting imprecise excision of SCCmec from the 
chromosome of the corresponding MRSA isolate (Donnio, Louvet et al. 2002; Donnio, 
Oliveira et al. 2005; Donnio, Fevrier et al. 2007; Shore, Rossney et al. 2008).  
As described in Chapter 1, SCCmec is a mobile genetic element that can either be integrated 
at or excised from the attachment site (attB) on the chromosome of S. aureus (Fig 3.1). This 
integration onto and excision of SCCmec from the chromosome is mediated by site specific 
recombinase enzymes encoded by the ccr complex on SCCmec. For integration, the 
recombinase enzymes recognize a 15bp nucleotide sequence, attB, upstream of orfX, which 
is recombined with a homologous sequence (attS) on SCCmec. After recombination, the 
attachment sites are duplicated on either side of the SCCmec to create left (attL) and right 
(attR) junctions between SCCmec and the chromosome. For excision, attL and attR are 
recombined by the recombinase enzymes to result in reconstituted attB and attS on the 
chromosome and the SCCmec, respectively. As attS is reconstituted, it forms a non-
replicating circular version of SCCmec (Noto and Archer 2006; Noto, Kreiswirth et al. 2008; 
Wang and Archer 2010). 
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attS
SCCmec
attRattL
attB
mec complex
ccr complex
orfX
orfX
ccr complex mec complex
Integrated SCCmec
Ccr mediated integration
Chromosome
SCCmec integration SCCmec excision
 
Figure 3.1: Integration and excision of SCCmec (Noto, Kreiswirth et al. 2008). For integration, the recombinase 
enzymes encoded by the ccr recognize the homologous 15bp sequence on SCCmec (attS) and S. aureus 
chromosome (attB). Following recombination, the 15bp sequences, attL and attR, flank SCCmec creating left 
and right junctions between SCCmec and the chromosome. For excision, attL and attR are recombined by the 
recombinase enzymes resulting in reconstituted attB and attS. As attS is reconstituted, it forms a non-
replicating circular SCCmec element.    
 
Occasionally, although the mechanism is not well understood, the excision of SCCmec from 
the chromosome can be imprecise, leaving some remnants of SCCmec within the attB site. 
Figure 3.2, adapted from Shore, et al. (2008), shows examples of imprecise excision of 
SCCmec from corresponding MRSA isolates which results in the presence of remnants of 
SCCmec in the resulting MSSA isolates.  
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ΔmecI
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mecRI
ΔmecI
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Tn554
ΔmecI
IS1182
dcs
orfX
attR
attR
dcs
attR
orfX
Type 4 ccr
attR
orfX
SCCmec IID (33 kb)
SCCmec IID remnant (26 kb)
from GrMSSA M06/0075. 
dcs-orfX (1.7 kb) from GrMSSA
M04/0269 
ccr4-orfX (7.5 kb)  from GrMSSA isolates , M02/0021,
M05/0146, M06/0004,
M06/0288
1
2
3
4
 
Figure 3.2: Representations of imprecise excision of SCCmec, adapted from Shore, et al. (2008). 1, 33kb 
SCCmec IID prototype; 2, 26kb remnant of SCCmec IID from GrMSSA isolate M06/0075 after loss of the 
fragment enclosed within IS1182 and dcs i.e. IS431, mecA, mecRI and one copy of the truncated mecI, from the 
parent strain; 3, 1.7kb remnant, dcs-orfX fragment of the SCCmec, from the GrMSSA isolate M04/0269; 4, 
7.5kb remnant, ccr4-orfX fragment of SCCmec, from the GrMSSA isolates M02/0021, M05/0146, M06/0004, 
M06/0288. Green line represents the approximate location of the SCCmec/SCC junction marking the divide 
between SCCmec IID and the ccrAB4 carrying element. 
 
The remnants (Fig 3.2), all showing similarity to elements of SCCmec IID, range between 
1.7kb to 26 kb in size, suggesting multiple independent losses of portions of SCCmec from 
the MRSA strains (Shore, Rossney et al. 2008). Table 3.1, adapted from Shore, et al. (2008), 
summarizes the reports of various SCCmec remnants in MSSA isolates from various studies.  
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Table 3.1: Summary of reports, adapted from Shore, et al. (2008), of SCCmec remnants in MSSA isolates from 
various studies reported between 2004 and 2011. 
 
No. of MSSA isolates 
with SCCmec regions 
(source; date) 
SCCmec remnants 
found 
MLST/spa 
genotype (n
*
)  
Reference 
7 (four Irish hospitals; 2002-2006) ccrAB2 
ccrAB4 
mecI; dcs 
ST8/t190 (4) 
ST8/t3209 (1) 
ST5/t088 (2) 
(Shore, Rossney et 
al. 2008) 
2 (i.v. drug users, UK; 2002-2003 ) ccrAB1 
dcs 
 
Not done 
 
(Corkill, Anson et 
al. 2004) 
26 (regions 
worldwide) 
Right SCCmec/orfX 
junction 
 
Not done (Huletsky, Giroux 
et al. 2004) 
6 (French hospitals; 1998-2002) IS431-pUB110, dcs 
IS431-pUB110-IS431-dcs 
 
ST8/t008 (1) (Donnio, Oliveira 
et al. 2005) 
1 (nasal swab, HCW, Germany) Right SCCmec/orfX 
junction 
t498 (Rupp, Fenner et 
al. 2006) 
169 (60 French 
Hospitals; 2002-2004) 
Right SCCmec/orfX 
junction 
dcs only 
HVR-IS431-pUB110- 
IS431-dcs 
 
 
ST8/t008 (1) 
ST8/t024 (1) 
(Donnio, Fevrier 
et al. 2007) 
51 (Östergötland County, Sweden; 
2004-2007) 
Right SCCmec/orfX 
junction 
 
12kb remnant of 
SCCmec II (1) 
CC5/t002 (49) (Lindqvist, 
Isaksson et al. 
2011) 
7 (USA and Cadanadian hospitals) SCCmec II specific 
remnants (kdp and J1 
region) 
dcs 
pUB110 
ccrAB2 
ST5 (Wong, Louie et 
al. 2010) 
*number of isolates characterized using spa typing and/or MLST. 
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The array of remnants of SCCmec in the MSSA isolates is inconsistent with the site-specific 
excision that is typical of Ccr mediated excision and therefore suggests the possibility of 
alternative mechanism(s) of SCCmec excision (Shore, Rossney et al. 2008). 
The instability of SCCmec in some MRSA lineages is common and has been reported in vitro 
as well as in some clinical isolates (Donnio, Louvet et al. 2002; Donnio, Oliveira et al. 2005; 
Donnio, Fevrier et al. 2007; Shore, Rossney et al. 2008; Noto, Fox et al. 2008; Lindqvist, 
Isaksson et al. 2011). In vitro loss of SCCmec has been attributed to a number of stressful 
conditions. Noto, Fox et al. (2008) reported in vitro loss of SCCmec from MRSA strains, 
following prolonged exposure to increasing levels of vancomycin, as a mechanism to 
compensate for chromosomal mutations that confer resistance to vancomycin which would 
otherwise add a cost to fitness to the strains. In some of the staphylococci, SCCmec was 
excised precisely while in others, remnants of SCCmec were retained in the attB site 
indicating partial excision of SCCmec (Noto, Fox et al. 2008).  
While factors that may contribute to partial excision of SCCmec in vivo may not be well 
understood, several studies have reported the occurrence of clinical isolates of MSSA with 
remnants of SCCmec in the attB site. As most MRSA are multi-drug resistant, the loss of 
SCCmec, may result in MSSA strains with resistance to a number of antibiotics other than β-
lactams (Donnio, Fevrier et al. 2007; Shore, Rossney et al. 2008; Lindqvist, Isaksson et al. 
2011).  A recent study (Donnio, et al. 2007) investigated 247 multi-drug resistant MSSA 
isolates, collected from 60 French hospitals between 2002 and 2004, to determine if the 
isolates resulted from a loss of SCCmec from corresponding MRSA strains, and to also 
monitor the spread of these strains with respect to the incidence of multi-drug resistant 
MSSA in the hospitals. Molecular analyses based on PFGE and Southern hybridization 
revealed evidence of MRSA background in 92% of the isolates. Furthermore, amplification of 
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various regions associated with SCCmec revealed evidence of remnants of this element in 
68% of the isolates. Moreover, 87.5% of the isolates which showed evidence of remnants of 
SCCmec were members of a single PFGE cluster and were associated with clonal complex 
(CC) 8. Most of these CC8 strains, following loss of SCCmec, showed clonal expansion and 
spread into high incidence hospitals as opposed to the other strains which showed 
independent loss of SCCmec in hospitals with a low incidence of these strains (Donnio, 
Fevrier et al. 2007).   
Another example of a multi-drug resistant (MDR) MSSA clone that became prevalent after 
loss of SCCmec was identified in a study by Lindqvist, et al. (2011), where 54 MDR-MSSA, 49 
of which were spa type t002 (MLST CC5) and were part of a clonal outbreak, were 
investigated for remnants of SCCmec in the attB site. The samples were collected from 
patients in Östergötland County, Sweden between January 2004 and October 2007. The 49 
isolates from the clonal outbreak, as well as two isolates from the additional collection, 
were positive for remnants of SCCmec thus accounting for 93% of the total isolates tested 
(Lindqvist, Isaksson et al. 2011). spa t002 was very common among MRSA isolates in 
Sweden during the period when the MSSA strains were isolated, demonstrating instability of 
SCCmec in a major MRSA clone.  
Monitoring of the epidemiology of MRSA populations in Irish hospitals between 1999 and 
2003, identified a change in the epidemicity of a multi-drug resistant clone ST8-MRSA-IIA-E 
(CC8), which accounted for 50% of the MRSA population in Irish hospitals in 1999, but was 
shown to be slowly being displaced by the non-multi-drug resistant ST22-MRSA-IV strain in 
the period between 1999 and 2003 (Shore, Rossney et al. 2008). Based on the suggestion 
that loss of SCCmec from epidemic strains may lead to changes in the evolution of MRSA in 
hospitals (Wagenvoort, Toenbreker et al. 2000; Donnio, Louvet et al. 2002), Shore, et al. 
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(2008) investigated for SCCmec components present in multi-drug resistant MSSA isolates 
recovered in Irish hospitals, and compared their genotypes to those of MRSA isolates 
previously identified in Ireland. Twenty five MDR-MSSA isolates, collected from six hospitals 
between 2004 and 2006, were investigated. The study reported the presence of SCCmec 
remnants in only seven of the isolates, five of which were CC8 while the remaining two were 
CC5. A variety of SCCmec remnants were identified in the CC8 isolates thus suggesting 
independent loss of SCCmec in the strains instead of clonal expansion of the strains 
following SCCmec excision. Interestingly, the SCCmec remnants in all five CC8 isolates 
showed similarity to components of SCCmec II (Fig 3.2) which suggested that the strains may 
have been derived from the previously predominant ST8-MRSA-II (Shore, Rossney et al. 
2008).  
In this context, MS14 may have resulted from a loss of SCCmec from a corresponding MRSA 
ST612 isolate while retaining the multi-drug resistance profile that is typical of this MRSA 
background. 
In addition, the relatedness of MS14 to ST612-MRSA-IV was investigated based on 
similarities in the nucleotide sequences of the rifampicin-resistance determining region 
(RRDR) of the rpoB gene.  Rifampicin inhibits transcription following its binding to the β-
subunit of the RNA polymerase encoded by rpoB. Several mutations in an internal fragment 
of the rpoB which result in changes in the amino acid sequence of the β-subunit have been 
reported to confer resistance to rifampicin (Aubry-Damon, Soussy et al. 1998). This 
mechanism of resistance to rifampicin has been reported in several bacterial species 
including Escherichia coli, Mycobacterium tuberculosis and S. aureus (Aubry-Damon, Soussy 
et al. 1998; O'Neill, Huovinen et al. 2006).  All the ST612-MRSA-IV isolates characterized by 
Jansen van Rensburg, et al. (2011) as well as the two ST612-MRSA-IV strains from Australia 
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and two additional ST612-MRSA-IV strains from South Africa, were shown to have identical 
amino acid substitutions (H481N, I527M) in the RRDR of the β-subunit (Jansen van Rensburg, 
Eliya Madikane et al. 2011). These amino acid substitutions are associated with high level 
rifampicin resistance and were not identified in any of the other rifampicin resistant strains 
characterized by Jansen van Rensburg, et al. (2011). In addition, all the ST612-MRSA-IV 
strains characterized (including the two isolates from Australia and the two from South 
Africa) had identical silent mutations in the RRDR thus supporting the suggestion of a 
common ancestor for the ST612-MRSA-IV strains. In this light, the relatedness of MS14 to 
ST612-MRSA-IV strains was investigated using the RRDR of the β-subunit of the isolates as a 
marker of genetic relatedness.  
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3.3 Materials and Methods 
3.3.1 S. aureus isolates 
 
MS14 (ST612-MSSA, spa type t064), isolated from a patient with septic arthritis at the Red 
Cross Children’s Hospital (Cape Town) in December 2008, was investigated in the current 
study. MS14 was resistant to penicillin, erythromycin, clindamycin, rifampicin, co-
trimoxazole and gentamicin. The control strains included MSSA NCTC 8325, MRSA COL and 
ST1-MRSA-IV (MW2) strains (all generously provided by Prof. Hermínia de Lencastre, 
Professor and Head, Laboratório de Genética Molecular, Instituto de Tecnologia Química e 
Biológica, Oeiras, Portugal) and MRSA SCH3304764 (ST612-MRSA-IV) (Jansen van Rensburg, 
Eliya Madikane et al. 2011). 
3.3.2 Extraction of whole-genomic DNA 
Genomic DNA was extracted from MS14 and the control strains as described [2.3.2]. 
3.3.3  Amplification of the attB site in MS14 
 The attB site, as shown in Fig 3.3, was amplified using the primer pair CL1 (5’- 
ATTTAATGTCCACCATTTAACA-3’) and CR1 (5’-AAGAATTGAACCAACGCATGA-3’) and PCR 
protocol described by Katayama, et al. (1999), to produce a 275bp amplicon.  
 
 
The PCR assay consisted of 1X PCR buffer, 1.5 mM MgCl2, 200 µM dNTPs, 1U SuperTherm 
Taq polymerase (all four items purchased from Southern Cross Biotechnology, Cape Town, 
South Africa), 0.5 µM  of each primer; and 200 ng of the genomic DNA extracts to a final 
volume of 50 µl. The PCR was carried out on the 2720 thermal cycler (Applied Biosystems, 
South Africa) with the cycling conditions as follows: initial denaturation at 95°C for 5 min 
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followed by 30 cycles of denaturation at 95°C for 1 min, annealing at 51°C for 1 min and 
extension at 72°C for 1 min with a final extension at 72°C for 5 min.  
MSSA NCTC 8325 strain was used as the positive control while MRSA COL strain was used as 
the negative control for the amplification. The PCR products were electrophoresed on 2% 
(w/v) agarose gel with 5 µl/100 ml (v/v) EtBr (10 mg/ml) at 80V for 95 minutes and then 
viewed under UV light.  
3.3.4 Detection of SCCmec remnants in MS14 
The detection of SCCmec elements involved amplification of various genes, normally 
associated with SCCmec cassettes (Fig 3.3), in individual assays.  
 
Figure 3.3: A schematic of SCCmec IV outlining the genes that were targeted for amplification. SCCmec is 
enclosed between attL and attR which are the left and right junctions respectively, between SCCmec and the 
chromosome. The conserved region, orfX, is indicated downstream of attR on the chromosome. The primer 
pairs for the amplification of each region are represented by the small black and grey arrows. 
 
The primer pairs and PCR protocols for the amplification of the different target regions are 
presented in Table 3.2. 
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Table 3.2: Primer pairs and PCR protocols for the amplification of the remnants of SCCmec in MS14. 
 
 
 
 
 
 
 
 
 
 
 
 
The positive controls were ST612-MRSA-IV for the amplification of mecA, ccrB2 and dcs 
regions and MRSA COL for dru. MSSA NCTC 8325 was used as a negative control for all 
assays. The PCR products were electrophoresed as described [3.2.3]. 
3.3.4.1 Determination of the location of dcs in MS14  
Following the amplification of dcs in MS14, the location of the locus in MS14 was 
determined by amplification of the right junction/orfX region of the SCCmec. The primer 
pair, dcs F2 (5’-GTCAATGAGATCATCTACAT-3’) and orfX R (5’-CCCAAGGGCAAGCGAC-3’), and 
the PCR protocol for the amplification of the 1701bp amplicon, were described by Shore, et 
al. (2008). 
The PCR assay consisted of 1X PCR buffer, 1.5 mM MgCl2, 200 µM dNTPs, 1.25U SuperTherm 
Taq polymerase (all four items purchased from Southern Cross Biotechnology, Cape Town, 
South Africa), 0.8 µM  of each primer; and 5 ng of the genomic DNA extracts to a final 
Primer 
pairs 
Primer nucleotide sequence 
(5’-3’) 
Gene Amplicon 
size 
Components 
in the PCR 
assays 
Amplification 
conditions 
Reference 
mecA P4 
 
mecA P7 
CCAGATTACAACTTCACCAGG 
 
CCACTTCATATCTTGTAACG 
mecA 162bp 1X PCR buffer; 
1.5 mM 
MgCl2; 
200 µM 
dNTPs; 1.2 U 
SuperTherm 
Taq 
polymerase;  
0.8 µM of 
each primer; 
and 5 ng of 
the genomic 
DNA  
Initial denaturation 
at 94°C for 4 min. 
30 cycles of 
denaturation at 
94°C for 30 s; 
annealing at 53°C 
for 30 s; extension 
at 72°C for 1 min; 
and final extension 
at 72°C for 4 min. 
(Milheirico, 
Oliveira et 
al. 2007) 
ccrB2 F2 
 
ccrB2 R2  
 
AGTTTCTCAGAATTCGAACG 
 
CCGATATAGAAWGGGTTAGC 
ccrB2 311bp 
dcs F2  
 
dcs R1  
 
CATCCTATGATAGCTTGGTC 
 
CTAAATCATAGCCATGACCG 
dcs 342bp 
dru1 
 
dru2 
GTTAGCATATTACCTCTCCTTGC 
 
GCCGATTGTGCTTGATGAG 
dru hyper-
variable 
region 
variable 1X PCR buffer; 
1.5 mM 
MgCl2; 
400 µM 
dNTPs; 1.25 U 
SuperTherm 
Taq 
polymerase;  
0.5 µM of 
each primer; 
and 100 ng of 
the genomic 
DNA  
Initial denaturation 
at 94°C for 2 min. 
30 cycles of 
denaturation at 
94°C for 1 min; 
annealing at 52°C 
for 1 min; extension 
at 72°C for 1 min; 
and final extension 
at 72°C for 3 min. 
(Goering, 
Shawar et 
al. 2008) 
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volume of 50 µl. The PCR was carried out on the 2720 thermal cycler (Applied Biosystems, 
South Africa) with the cycling conditions as follows: initial denaturation at 94°C for 4 min 
followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 30 s and 
extension at 72°C for 1 min with a final extension at 72°C for 4 min.  
For the amplification, ST612-MRSA-IV and MW2 were used as positive controls while MSSA 
NCTC 8325 was used as a negative control. The PCR products were electrophoresed as 
described [3.2.3]. 
Amplicons were purified and sequenced as described [2.3.3.1]. The primers used for the PCR 
assay were also used for the sequencing of the amplicons. Sequence analysis was carried 
out using the sequence alignment editor and analysis program, BioEdit v7.0.5 (Ibis 
Biosciences, California, USA). 
3.3.5 PCR amplification and sequencing of rifampicin-resistance determining region of 
rpoB of MS14 
The rifampicin-resistance determining region of the rpoB gene of MS14 was amplified using 
the primer pair previously described by Aubry-Damon, et al. (1998), rpoB F3 (5’-
AGTCTATCACACCTCAACAA-3’), and rpoB F4 (5’-TAATAGCCGCACCAGAATCA-3’) to produce a 
702bp amplicon.  
The PCR assay consisted of 1X PCR buffer, 1.5 mM MgCl2, 400 µM dNTPs, 1U SuperTherm 
Taq polymerase (all four items purchased from Southern Cross Biotechnology, Cape Town, 
South Africa), 40 pmol of each primer; and 100 ng of the genomic DNA extracts to a final 
volume of 100 µl. The PCR was carried out on the 2720 thermal cycler (Applied Biosystems, 
South Africa) with the cycling conditions as follows: initial denaturation at 94°C for 4 min 
followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 52°C for 45 s and 
extension at 72°C for 45 s with a final extension at 72°C for 3 min.  
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The PCR products were separated by gel electrophoresis and purified [2.3.3.1]. The purified 
products were sequenced, using the same primer pairs used for PCR, at the Central 
Analytical Facility in Stellenbosch.  
Sequence analysis began with alignment of the generated sequences to a reference 
sequence of the rpoB (X64172 from a rifampicin susceptible S. aureus RN4220), retrieved 
from GenBank (http://ncbi.nlm.nih.gov), using the sequence alignment editor and analysis 
programme, BioEdit v7.0.5 (Ibis Biosciences, California, USA).The aligned sequences were 
then translated into the corresponding amino acid sequences. The amino acid sequences 
were also aligned to ensure that the query sequence was in the correct frame as the 
reference sequence so as to determine the type and location of any changes in the query 
sequence.  
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
76 
 
3.4  Results 
3.4.1 Amplification of the attB site in MS14 
 
 As a first step to understanding the genetic arrangement at the attB site in MS14, a PCR 
assay was carried out using the primer pairs [3.2.3] which anneal to attL and attR 
respectively (Fig 3.3). As shown in Fig 3.4, a product of the expected size (275bp) was 
obtained from MSSA NCTC 8325. Also as expected, no product was obtained for MRSA COL 
containing SCCmec I, which is too large for PCR amplification. Similarly no product was 
obtained with the MS14 indicating that it contains an insert in the attB site.  
      
Figure 3.4: Gel electrophoresis of the attB amplicons. H1 and H4, molecular weight markers, Hyperladder 1
TM
 
and HyperLadder IV
TM
 respectively (Celtic Molecular Diagnostics, Cape Town, South Africa). H2O, the water 
control which was used as a DNA negative control for the reaction. 
 
 
3.4.2 PCR for the detection of remnants of SCCmec 
 
To determine the identity of the insert at the attB site in MS14, PCR assays were carried out 
for the detection of SCCmec components using the primer pairs described [3.2.4]. Of the 
different loci (mecA, dru, ccrB2 and dcs) targeted on SCCmec, a product was obtained only 
for dcs (Fig 3.5).  
       H1                                 MS14      COL     NCTC 8325     H2O                        H4     
300bp 
200bp 
100bp 
NCTC 
8325 
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Figure 3.5: Gel electrophoresis of the PCR products for the detection of remnants of SCCmec in MS14. The 
internal loci (mecA, dru, ccrB2 and dcs) of SCCmec were targeted for amplification. ST612-MRSA-IV was 
included as a positive control for the amplification of mecA, ccrB2 and dcs while MRSA COL was included as a 
positive control for dru. MSSA NCTC 8325 was included in the PCR assays as a negative control for all four loci. 
H1 and H4, molecular weight markers, Hyperladder 1
TM
 and HyperLadder IV
TM
 respectively (Celtic Molecular 
Diagnostics, Cape Town, South Africa). H2O, the water control which was used as a DNA negative control for 
the reaction. 
 
3.4.2.1 Determination of the location of dcs in MS14 
 
To ascertain whether dcs is associated with attB site in MS14, a PCR assay was performed 
using primers dcs F2 and orfX R [3.2.4.1].   
 
Figure 3.6: Gel electrophoresis of the amplicons for the determination of the location of dcs in MS14. ST612-
MRSA-IV (SCCmec IVd) and MW2 (SCCmec IVa) were used as positive controls while MSSA NCTC 8325 was used 
as a negative control. H1, molecular weight marker, Hyperladder 1
TM
 (Celtic Molecular Diagnostics, Cape Town, 
South Africa). H2O, the water control which was used as a DNA negative control for the reaction. 
         H1               MS14                                 NCTC 8325           MW2                          H20 
2000bp 
1500bp 
MRSA 
ST612   
MS14                        H20            H4            MS14                          H20         MS14                          H20             H1 
MRSA 
COL 
NCTC 
8325 
NCTC 
8325    
NCTC 
8325   
MRSA 
ST612 
MRSA 
ST612 
MRSA 
ST612 
 H4  MS14                              H20 
100bp 
200bp 
300bp 
500bp 
700bp 
800bp 
400bp 
600bp 
mecA dru ccrB2 dcs 
NCTC 
8325 
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Amplicons (1.7kb) were obtained with the ST612-MRSA-IV and MW2 (SCCmec IVa) strains as 
well as with MS14. The product from MS14 was purified and sequenced [2.3.3.1]. Sequences 
were obtained with the primers, dcs F2 (1077bp) and orfX R (1256bp), respectively. 
Alignment of the data with the corresponding sequences of SCCmec IVa of MRSA JCSC 4469 
(AB097677), acquired from Genbank (http://www.ncbi.nlm.nih.gov/genbank/), showed 97% 
and 92% sequence similarity with dcs and  orfX, respectively. 
 
3.4.3  PCR and Characterization of the rifampicin-resistance determining region (RRDR) of 
MS14 
Following PCR of the RRDR of rpoB of MS14, the 702bp product was sequenced [3.2.5]. 
Alignment of the sequencing data with the corresponding region from a rifampicin 
susceptible S. aureus (X64172 from S. aureus RN4220) as well as from ST612-MRSA-IV, 
revealed the mutations: C→A, G→T, T→C and T→G at nucleotide positions 2662, 2715, 
2757, and 2802 respectively, present in both ST612-MRSA-IV and MS14 (Fig 3.7). Translation 
of the rpoB nucleotide sequence into an amino acid sequence revealed amino acid 
substitutions H481N and I527M corresponding to  C→A (2662) and  T→G (2802) mutations  
respectively, located in the RRDR of MS14 and ST612-MRSA-IV. The G→T (2715) and T→C 
(2757) mutations did not result in changes in the corresponding amino acids. 
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Nucleotide position 2650      2660      2670      2680      2690      2700    
....|....|....|....|....|....|....|....|....|....|....|....|
ST612-MRSA-IV AACCCATTAGCTGAGTTAACGAATAAACGTCGTCTATCAGCATTAGGACCTGGTGGTTTA
N  P  L  A  E  L  T  N  K  R  R L  S  A  L  G  P  G  G L 
MS14      AACCCATTAGCTGAGTTAACGAATAAACGTCGTCTATCAGCATTAGGACCTGGTGGTTTA
N  P  L  A  E  L  T  N  K  R  R L  S  A  L  G  P  G  G L 
rpoB ref seq AACCCATTAGCTGAGTTAACGCATAAACGTCGTCTATCAGCATTAGGACCTGGTGGTTTA
N  P  L  A  E  L  T  H  K  R  R L  S  A  L  G  P  G  G L 
Amino acid position    474                  481                                 493
Nucleotide position           2710      2720      2730      2740      2750      2760    
....|....|....|....|....|....|....|....|....|....|....|....|
ST612-MRSA-IV ACACGTGAACGTGCTCAAATGGAAGTACGTGACGTTCACTACTCTCACTATGGCCGCATG
T  R  E  R  A  Q  M  E  V  R  D  V  H  Y  S  H  Y  G  R  M 
MS14                   ACACGTGAACGTGCTCAAATGGAAGTACGTGACGTTCACTACTCTCACTATGGCCGCATG
T  R  E  R  A  Q  M  E  V  R  D  V  H  Y  S  H  Y  G  R  M 
rpoB ref seq ACACGTGAACGTGCGCAAATGGAAGTACGTGACGTTCACTACTCTCACTATGGCCGTATG
T  R  E  R  A  Q  M  E  V  R  D  V  H  Y  S  H  Y  G  R  M 
Amino acid position    494                                                      513
Cluster I
Cluster II
Nucleotide position 2770      2780      2790      2800      2810      2820    
....|....|....|....|....|....|....|....|....|....|....|....|
ST612-MRSA-IV TGTCCAATTGAAACACCTGAGGGACCAAACATTGGATTGATGAACTCATTATCAAGTTAT
C  P  I  E  T  P  E  G  P  N  I  G  L  M  N  S  L  S  S Y 
MS14      TGTCCAATTGAAACACCTGAGGGACCAAACATTGGATTGATGAACTCATTATCAAGTTAT
C  P  I  E  T  P  E  G  P  N  I  G  L  M  N  S  L  S  S Y 
rpoB ref seq TGTCCAATTGAAACACCTGAGGGACCAAACATTGGATTGATTAACTCATTATCAAGTTAT
C  P  I  E  T  P  E  G  P  N  I  G  L  I  N  S  L  S  S Y 
Amino acid position    514                                    527               533
Figure 3.7:  Alignment of the internal fragment of the rifampicin-resistance determining region of rpoB 
nucleotide sequences and the corresponding amino acid sequences of MS14, ST612-MRSA-IV and a rpoB 
reference sequence (X64172 from a rifampicin susceptible S. aureus RN4220).  Clusters I and II are sequences 
internal to the RRDR where most mutations associated with rifampicin resistance occur. 
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3.5 Discussion 
MS14, isolated from a patient with septic arthritis at the Red Cross Children’s Hospital in 
December 2008, was identified as ST612-MSSA-t064. It was resistant to penicillin, 
erythromycin, clindamycin, rifampicin, co-trimoxazole and gentamicin and was sensitive to 
cloxacillin, ciprofloxacin, fusidic acid, vancomycin and linezolid.  This antibiotic susceptibility 
pattern was similar to that seen in ST612-MRSA-IV isolates (Jansen van Rensburg, Eliya 
Madikane et al. 2011).   
Recent studies have suggested that multi-drug resistant MSSA isolates in hospitals 
frequently result from either precise or imprecise excision of SCCmec from corresponding 
MRSA (Donnio, Louvet et al. 2002; Donnio, Oliveira et al. 2005; Donnio, Fevrier et al. 2007; 
Shore, Rossney et al. 2008; Lindqvist, Isaksson et al. 2011). This raised the question of 
whether MS14 arose as a result of a loss of SCCmec from a corresponding ST612-MRSA 
strain.  
Of the different SCCmec components investigated, only dcs was detected. This gene is the 
common downstream sequence associated with SCCmec I, II and IV and is located 
immediately upstream of the right junction/orfX region on these elements as shown for 
SCCmec II and IV in Fig 3.2 and Fig 3.3, respectively.  
Even though dcs has been classified as SCCmec-related, Wong, et al. (2010) have reported 
the presence of this gene immediately downstream of orfX in some MSSA strains. In the 
same study, some isolates of MRSA were shown to contain a second copy of dcs outside of 
SCCmec, adjacent to attL. In MS14, a PCR assay and sequencing of the amplicons confirmed 
the presence of dcs within SCCmec related sequences, suggesting that this strain arose due 
to partial excision of SCCmec from ST612-MRSA. 
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Support for this suggestion comes from the investigation of the relatedness of MS14 to 
ST612-MRSA-IV using the nucleotide sequences of the RRDR of rpoB as a marker of 
relatedness. Jansen van Rensburg, et al. (2011) identified two amino acid substitutions 
(H481N, I527M) in the RRDR of the β-subunit of the RNA polymerase in local ST612-MRSA-IV 
strains as well as in the two Australian strains but not in any of the other rifampicin resistant 
strains in the study. Further, all of the isolates investigated contained the single nucleotide 
polymorphism (SNP), CGT → CGC, at amino acid position 512. This silent SNP and the amino 
acid substitutions identified in ST612-MRSA-IV isolates were also identified in MS14, 
suggesting the strains are related.  
As shown in Table 3.1, the presence of dcs in MSSA strains, shown to be the result of a 
partial loss of SCCmec, has been identified previously. As described in [3.2], of the seven 
MSSA isolates investigated by Shore, et al. (2008) one isolate contained dcs 1.7kb 
downstream of orfX in the right junction/orfX region. Similarly, in the study by Lindqvist, et 
al. (2011), elaborated in [3.2], 51 of the 54 samples, which were investigated for remnants 
of SCCmec, carried dcs at the right junction/orfX region. Forty nine of the isolates which 
carried dcs were from a clonal outbreak, suggesting expansion of a clone following partial 
excision of SCCmec.  
The dcs region has also been identified in combination with other remnants of SCCmec in 
MSSA. In the study by Donnio, et al. (2007) (expanded in [3.2]), 169 of the 247 MDR-MSSA 
isolates investigated contained remnants of SCCmec. Of the 169 isolates, 141 had spa types 
(t008 (n=104), t024 (n=7), other (n=30)) associated with CC8. A representative strain from 
spa t008 was shown to have a HVR-IS431-pUB110-IS431-dcs fragment associated with the 
right junction on SCCmec IA, II, and IVA.  
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For the purpose of the current study, the identification of the dcs region in the attB site in 
MS14 confirmed the presence of a SCCmec remnant in the strain and therefore further 
characterization of the insert was not conducted. While the findings were insufficient to 
determine whether dcs in MS14 emanated from SCCmec IV, the fact that no other SCCmec 
was identified in association with ST612-MRSA (Jansen van Rensburg, Eliya Madikane et al. 
2011) supports such a suggestion.  
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CHAPTER 4 
___________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
Which is fitter: MS14 or ST612-MRSA-IV? 
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4.1 Abstract 
Evidence presented in the previous chapters suggested that MS14 resulted from a partial 
loss of SCCmec from a corresponding ST612-MRSA strain. Studies have associated fitness 
advantage with the loss of this element. The study described in this chapter compared 
fitness between MS14 and ST612-MRSA-IV strains (D4, E3, E8 and S5). 
Exponential phase growth rates of the resistant strains, relative to MS14, revealed a slower 
growth rate for S5 while E3, E8 and D4 grew at similar rates to MS14. 
Competition between the resistant strains and MS14 was investigated with 24-hour and 
five-day pairwise competition assays. Collectively these assays revealed a reduction in the 
fitness of the resistant strains, with the exception of D4, relative to MS14.  
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4.2 Introduction 
Evidence presented in the previous chapters suggested that MS14 resulted from a partial 
loss of SCCmec from a corresponding ST612-MRSA strain. Loss of SCCmec has been shown to 
occur spontaneously; studies have associated this loss with an increase in fitness (Ender, 
McCallum et al. 2004; Lee, Ender et al. 2007; Noto, Fox et al. 2008) where fitness is defined 
as the ability of bacteria to grow and survive in a specific environment. Nϋbel, et al. (2008) 
suggested that bacterial strains are likely to predominate in environments for which they 
are best fitted. When fitness is compromised the bacterial population may be vulnerable to 
being displaced by a stronger competitor in the same environment.   
Cost to fitness in bacteria may be due to a number of factors, including the acquisition of 
extra-chromosomal elements, which carry antibiotic resistance genes, as well as 
chromosomal mutations which alter the target of an ntibiotic, thus reducing its affinity for 
the antibiotic (Levin, Lipsitch et al 1997; Andersson and Levin 1999). For example, amino 
acid substitutions in the RNA polymerase, the target for rifampicin, confers resistance to this 
antibiotic in a number of organisms, but frequently at a fitness cost to the host (Billington, 
McHugh et al. 1999; Reynolds 2000; Wichelhaus, Boddinghaus et al. 2002; Mariam, 
Mengistu et al. 2004; O'Neill, Huovinen et al. 2006). A study by Wilchelhaus, et al. (2002) 
compared fitness of a rifampicin susceptible S. aureus strain with a number of its isogenic 
resistant counterparts, each with a different mutation associated with rifampicin resistance. 
Compared to the parent, pairwise competition assays revealed that with the exception of 
H481N, all the substitutions imposed a fitness cost, to varying degrees, on the host. In a 
similar assay involving a rifampicin susceptible reference S. aureus strain and its resistant 
mutants, O’Neill, et al. (2006) reported a correlation between relative fitness of the isogenic 
test strain and its rifampicin MIC. Strains with mutations associated with high rifampicin 
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MICs were less fit than their counterparts with low MICs. Interestingly, unlike in the study of 
Wilchelhaus, et al, O’Neill, et al observed a fitness cost in a strain carrying the H481N 
substitution, even though this strain had a MIC of only 2 µg/ml, which is the equivalent of 
the MIC interpretative standard for intermediate resistance to rifampicin in S. aureus (CLSI 
2009). 
It is often the acquisition, as well as the maintenance of extra-chromosomal elements, 
which impose fitness cost on the host (Andersson and Levin 1999; Foucault, Courvalin et al. 
2009; LaMarre, Locke et al. 2011). A good example is cfr, which encodes a rRNA 
methyltransferase that modifies a conserved adenine in the 23SrRNA, thus conferring 
resistance to antibiotics such as linezolid (LaMarre, Locke et al. 2011). In 2005, this gene, 
often plasmid borne in staphylococcal isolates from animals, was identified located on the 
chromosome in a linezolid resistant MRSA isolate from a patient in Medellin, Columbia (Toh, 
Xiong et al. 2007). In this MRSA, cfr was l cated downstream of ermB (erm (B)), a rRNA 
methyltransferase that modifies another adenine in the same region as cfr. Both genes are 
co-expressed in the mlr operon under the Perm promoter (Toh, Xiong et al. 2007). In their 
study, LaMarre, et al. (2011) reported a fitness cost, albeit low at 4.6% per generation, 
associated with basal expression of cfr when pairwise competition assays were carried out 
between two isogenic MRSA strains; one expressing cfr on a plasmid vector and the other 
carrying the empty vector. Interestingly, in similar experiments, competition between two 
isogenic MRSA strains carrying plasmid borne cfr::ermB, with or without an active cfr, 
revealed a significant increase of 10.6% in the cost to fitness of cfr with the co-expression of 
ermB (LaMarre, Locke et al. 2011). 
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Foucault, et al. (2009) also reported similar findings in which the acquisition and basal 
expression of the vanA operon, which encodes VanA-type glycopeptide resistance in S. 
aureus strains, was suggested to impose fitness cost on its MRSA host. In the study, the 
authors compared fitness between a vanA naïve MRSA strain, HIP11713, and its vanA 
transconjugant MRSA strain, VRSA-1. The vanA operon, in VRSA-1, is carried on a 
transposon, Tn1546, which in turn is carried on a multi-copy resident plasmid.  Pairwise 
competition assays between the isogenic strains revealed a slight decrease in the fitness of 
the transconjugant strain in comparison to the susceptible strain, in the absence of 
vancomycin, suggesting a fitness disadvantage to the acquisition and basal expression of the 
vanA operon. 
Similarly, the acquisition and basal expression of mecA has been reported to impose fitness 
cost on S. aureus strains (Noto, Fox et al. 2008). In their study, Noto, Fox et al. (2008) 
identified S. aureus strains which recovered their fitness, when serial passage in increasing 
concentrations of vancomycin promoted partial loss of SCCmec. To investigate if the loss of 
mecA contributed to the recovery in fitness of the vancomycin resistant strains, the authors 
compared fitness between MRSA 3130V32 and its mecA inactivated variant, 
3130V32ΔmecA, which were recovered following serial passage in increasing concentrations 
of vancomycin. An eight-day pairwise competition assay between the two strains revealed 
poor survival of 3130V32, suggesting a fitness advantage to the inactivation of mecA. 
Further experiments, in which the authors compared fitness between vancomycin 
susceptible MRSA and their mecA inactivated MSSA counterparts, revealed that the fitness 
cost imposed by the carriage of mecA was not limited to vancomycin resistant strains, 
suggesting that cost to fitness is a consequence of the expression of mecA in S. aureus 
strains (Noto, Fox et al. 2008).  
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Other studies have suggested that when compared to MRSA-IV strains, cost to fitness is 
increased in MRSA carrying SCCmec types I and II which frequently contain additional 
resistance genes (Lee, Ender et al. 2007; Collins, Rudkin et al. 2010). Relevant to the current 
study, Collins, Rudkin et al. (2010) compared fitness of clinical MRSA (CC8-MRSA-IV, CC22-
MRSA-IV and CC30-MRSA-II) and related MSSA against a marker strain, MSSA 466. A cost to 
fitness on the clinical strains was associated with the presence of both mec types with a 
lower fitness cost associated with SCCmec IV while SCCmec II exerted a significantly higher 
cost (Collins, Rudkin et al. 2010). In this context, the author considered the possibility that 
MS14 could be fitter than ST612-MRSA-IV strains.  
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4.3 Materials and Methods 
 
4.3.1 S. aureus isolates used in this study 
The MRSA and MSSA strains investigated as part of this study were presented in Tables 2.1 
and 2.2, but for clarity of reading, the strains are further described in Table 4.1. 
Table 4.1: S. aureus strains used in the current study 
Isolate Phenotype MLST spa type PFGE                                       Antibiogram  
P Clo E Cli R Co Ci G F V L 
MS14 MSSA ST612 t064 D* R S R R R R S R S S S 
D4 MRSA ST612 t064 D R R R R R R S R S S S 
E3 MRSA ST612 t1443 E R R S S R R R R S S S 
E8 MRSA ST612 t064 E R R R R R R R R S S S 
S5 MRSA ST612 t064 Sporadic R R S S R R S R S S S 
*typed in the current study 
P, penicillin; Clo, cloxacillin; E, erythromycin; Cli, clindamycin; Rif, rifampicin; Co, co-trimoxazole; Ci, 
ciprofloxazin; G, gentamicin; F, fusidic acid; V, vancomycin; L, linezolid. R, resistant; S, susceptible. 
4.3.2 Synchronization of the initial inocula 
The initial inocula for the comparative assays were synchronized to exponential phase. This 
involved determining duration to exponential phase and the OD 600 nm values at these 
time points in the growth of the individual strains.  
4.3.2.1 Determining duration to exponential phase and the OD 600 nm values at 
these time points  
From the 50% glycerol stocks [2.3.1], each isolate was streaked for single colonies on boiled 
blood agar plates (Green point NHLS laboratories, Cape Town) and incubated overnight at 
37°C. For each strain, a single colony from the overnight culture was inoculated into 5 ml 
2YT broth [Appendix (A) 1.1]. Using a plastic loop, the cells were homogenized in the broth 
and then three 300 µl aliquots of each of the broth cultures were transferred onto a 100 
honeycomb micro-well plate. The plate was transferred onto the Bioscreen C 
Microbiological Reader (Thermo Electron Corporation, USA), an automated incubator and 
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OD reader system for monitoring the growth of microorganisms [A2.1]. This system consists 
of three components: the incubator, OD reader and the automated data analysis application 
(Research Express Software, Transgalatic, USA).  
The system was programmed to incubate the bacterial cultures at 37°C for 24 hours, 
automatically recording OD 600 nm readings every 30 minutes. Using the software 
provided, growth curves were generated which were used to establish duration to 
exponential phase and the OD 600 nm value at this time point for each strain.  
4.3.2.2 Cultivation of exponential phase cells  
Single colonies for each strain were obtained and the cells were then grown to exponential 
phase as described [4.3.2.1]. Based on the data obtained from 4.3.2.1, incubation was 
terminated at exponential phase. A 250 µl aliquot of the exponential phase culture from 
each of four individual wells, for each strain, was added to 250 µl of 50% glycerol solution 
[A1.3].  
For each strain, a representative glycerol stock vial was used to determine the number of 
CFUs prior to storage at -80°C. Initially, 106–fold serial dilutions of the stocks were prepared 
in 1X PBS, on a 96-well round bottom micro-titre plate (Adcock Ingram, Johannesburg, 
South Africa). Then 10 µl of the 104 to 106 dilutions was plated in duplicate on 2YT agar 
[A1.2], and incubated at 37 °C overnight (Fig 4.1). 
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glycerol stock
PBS (180 µl) 
20 µl
20 µl20 µl20 µl20 µl20 µl
101
106
104
105
106105104103102
In duplicate
10 µl
2 YT agar
Dilution factor
10 µl
10 µl
 
Figure 4.1: The dilution series for the quantification of the viable cell count. The glycerol stocks were diluted 
six fold at a 1: 10 ratio in PBS solution on a 96-well round bottom micro-titre plate (Adcock Ingram, 
Johannesburg, South Africa), represented by the blue vials. An aliquot of 10 µl of the 10
4
 to 10
6
 dilutions was 
plated in duplicate on 2YT agar, and then incubated overnight at 37°C. 
 
 
The CFUs in the glycerol stocks were calculated as follows: 
 Average nō. of colonies     X    Total dilution factor = CFUml-1 
 
The dilution yielding between 10 to ≤ 100 colonies was acceptable for the experiments, 
taking into account the congruence in the dilutions.  Following quantification, the cells were 
stored at -80°C. To confirm that the viability of the cells was not compromised during 
storage, quantification of CFUs was repeated after 24 hours of storage.  
4.3.3 Comparison of the growth kinetics of the strains 
The protocol described by Lindqvist, R (2006) for the comparison of individual strain growth 
rates, based on turbidity measurements, was adapted. Initially, the glycerol stocks of the 
individual strains were diluted, in a 96-well round bottom micro-titre plate, to 105 CFUml-1 in 
1X PBS and then to 104 CFUml-1 in 2YT broth (Fig 4.2).   
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50% glycerol stock
108 CFUml-1
225 µl PBS
25 µl
25 µl
25 µl
25 µl25 µl25 µl
101 10
4
103102 Dilution factor
107 106 105 10
4 CFUml-1
225 µl 2YT broth
Determination of  the 
viable cell count to 
monitor 50% glycerol 
stock  
      
Figure 4.2: The serial dilution of the glycerol stocks for each strain. The stocks ere initially diluted to 10
5 
CFUml
-1
 in 1 XPBS then 25 µl transferred into 225 µl of 2YT broth to a final concentration of 10
4
 CFUml
-1
. 
Concurrently with the comparison of growth rates, the viability of the cells was monitored following storage at 
-80°C. Broken arrow indicates a series of steps which included the dilution and subsequent plating of the 
samples to determine the viable cell count. 
 
Triplicate aliquots of 250 µl of the 104 CFUml-1 broth cultures were transferred onto a 
honeycomb plate, and cultured for 24 h urs using the Bioscreen C system [4.3.2.1]. 
Concurrently, the viability of the cells was monitored following storage at -80°C as a control 
[4.3.2.3]. 
The growth rates (µ) per independent culture were calculated based on the equation 
described below (Foucault, Courvalin et al. 2009): 
      µ = [lnNt-lnN0]/ (t-t0); where N represents the OD 600 nm values at two time points (t) 
over which growth increased exponentially. 
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4.3.4 Pairwise competition assays between S. aureus strains 
Twenty four-hour and five-day pairwise competition experiments, adapted from the 
protocols previously described by Laurent, Lelievre et al. (2001) and Ender, McCallum et al. 
(2004), respectively, were carried out between MS14 and representative ST612-MRSA-IV 
strains in individual assays. In both experiments, cefoxitin (4 µg/ml), a surrogate for 
methicillin as per CLSI guidelines (CLSI 2009), was added to 2YT agar to select for the 
resistant strains. 
4.3.4.1 Twenty four-hour pairwise competition assays between MS14 and ST612-
MRSA-IV 
 Initially, 24-hour pairwise competition experiments, adapted from the protocol described 
by Laurent, Lelievre et al. (2001), were carried out, in duplicate. Serial dilutions of the 
glycerol stocks were prepared as shown in Fig 4.2. Then, 100 µl of 106 CFUml-1 each of the 
resistant and susceptible strains was inoculated into 10 ml 2YT broth in a 100 ml Erlenmeyer 
flask, to give initial inocula of 105 CFUs each (Fig 4.3). 
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MS14 ST612-MRSA-IV 
-37°C
- 24 hrs
10 ml 2YT 
broth
Sampling (hrs) 
t0, 4, 6, 10, 24
2YT agar 2YT agar + Cefoxitin (4 µg/ml)
10x
10y
10z10x
10y
10z
-105 CFUs-105 CFUs
20 µl diluted for 
plating
10 µl 10 µl
 
Figure 4.3: Flow diagram depicting the 24-hour pairwise competition assays with MS14 and the ST612-MRSA-
IV strains. A volume of 100 µl of 10
6
 CFUml
-1
 of each of the resistant and susceptible strains was inoculated 
into 10 ml 2YT broth in a 100 ml Erlenmeyer flask, to give 10
5 
CFUs, and incubated at 37°C with shaking (100 
rpm). At specific time points as indicated, 20 µl of the culture was removed, diluted and 10 µl of the respective 
dilutions plated, in parallel, on non-selective 2YT agar and on selective 2YT agar media containing 4 µg/ml 
cefoxitin (as per CLSI guidelines (CLSI 2009)). 10
x
, 10
y
 and 10
z
, the dilution factors for the respective dilutions 
plated. All the experiments were carried out in duplicate. 
 
For the calculation of the CFUs for the susceptible and resistant strains in the individual 
assays, the total cell count was determined by plating the mixed cultures on non-selective 
2YT agar media. The CFUs for the resistant strain, determined by plating on selective 2YT 
agar media containing 4 µg/ml cefoxitin, were subtracted from the total cell count to give 
the CFUs for the susceptible strain.  
 
4.3.4.2  Five-day mixed culture competition assays between MS14 and ST612-MRSA-
IV 
Five-day pairwise competition experiments, adapted from the protocol described by Enders, 
et al. (2004), were carried out. Serial dilutions of the glycerol stocks were conducted 
[4.3.2.3] to obtain 104 CFUs as initial inocula for individual strains. The assays proceeded as 
depicted in Fig 4.4. 
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broth
Day 1
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10z 10
x
10y
10z 10x
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Day 2
20 µl 
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dilution 
100 µl 
20 µl  diluted 
for plating 20 µl  diluted 
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20 µl 
2YT agar 2YT agar +
Cefoxitin (4 µg/ml)
Day 3,4,5
10 ml 2YT 
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Figure 4.4: The flow diagram depicting the five-day pairwise competition assays with MS14 and the ST612-
MRSA-IV strains. A volume of 100 µl of 10
6
 CFUml
-1
 of each of the resistant and susceptible strains was 
inoculated into 10 ml 2YT broth in a 100 ml Erlenmeyer flask, to give 10
5
CFUs, and incubated at 37°C with 
shaking (100 rpm). At 24-hour intervals, 20 µl of the culture was removed, diluted and 10 µl of the respective 
dilutions plated, in parallel, on non-selective 2YT agar and on selective 2YT agar media containing 4 µg/ml 
cefoxitin (as per CLSI guidelines (CLSI 2009)).  100 µl of the 10
4 
dilution of the 24-hour culture was transferred 
into 10 ml fresh 2YT broth in a 100 ml Erlenmeyer flask, incubated under the same conditions as before, in a 
serial passage over a four day period. 10
x
, 10
y
 and 10
z
, the dilution factors for the respective dilutions plated. 
Broken arrows indicate a series of steps in the serial dilution of the cultures. All the experiments were carried 
out in duplicate.  
 
 
 
 
4.3.4.3 Data analyses for the pairwise competition assays 
For the investigation of the competition between MS14 and the ST612-MRSA-IV strains, two 
methods were used: 1) end point analyses which compared the ratio of the colony forming 
units for each individual strain at the beginning (t0) and the end (tn) of the assay (Laurent, 
Lelièvre et al. 2001); 2) calculation of the relative fitness of the resistant strains in 
comparison to MS14 which was based on the equations below (Foucault, Courvalin et al. 
2009; Billington, McHugh et al. 1999): 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
96 
 
        Generation number (g) = (logB – logA)/ log2; where A and B were colony forming units 
for each individual strain at the beginning and the end of the assay, respectively. 
        Relative fitness (RF) = gR/gS; where gR is the average generation number of the resistant 
strain and gS  the average generation number of the susceptible strain. 
 
4.3.5 PFGE for the relatedness of MS14 to D4 
The results of the competition assays indicated that it was necessary to carry out PFGE to 
better understand the relatedness of MS14 to the resistant isolates, particularly D4. PFGE 
[1.4.1.1] was carried out based on the protocol described by Reed, Stemper et al. (2007). 
The strains used in this experiment included, MS14, and the comparators, D4, E3, E8 and S5. 
From the glycerol stocks [4.3.2.2], individual strains were plated on 2YT agar and incubated 
overnight at 37°C. For each strain, a sweep of colonies was suspended in 2 ml TEN buffer 
[A4.1] in a sterile universal bottle and the turbidity adjusted to between OD 600 nm 0.825 - 
0.875 using the Spectronic Biomate 5 UV-Vis (Thermo Electron Corporation, USA).  
For the preparation of the plugs, 250 µl of the cell suspension of each of the isolates was 
transferred into a sterile 2 ml tube, to which 5 µl of lysostaphin was added, followed by 250 
µl of molten 1.8% (w/v) Seakem Gold Agarose gel (Cambrex BioScience, Rockland, USA), 
prepared as outlined in A4.2. The mixture was immediately homogenised by pipetting up 
and down and 250 µl aliquoted into plug moulds to form two plugs per suspension, which 
were then allowed to solidify at 4°C for 10 min.  
To obtain intact genomic DNA each of the isolates was lysed in situ by submerging the 
agarose plugs in 2 ml EC buffer [A4.3], which had been pre-warmed to 37°C, and incubating 
the plugs at 37°C for 4 hours to facilitate digestion of the cell wall and membrane. 
Subsequently, the EC buffer was decanted and replaced with 2 ml ESP buffer [A4.4]. The 
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plugs were then incubated at 55°C for 16 hours; after which the plugs were transferred to 
sterile universal bottles and submerged in 10 ml TE buffer [A4.5].  
The universal bottles were then placed on a variable speed rotor at 30 rpm. After 30 min, 
the buffer was decanted, replaced with 10 ml fresh TE buffer, and then placed on the rotor 
for a further 30 min. These washes were repeated three times with fresh TE buffer. 
The genomic DNA obtained was digested with SmaI. Using a blade, a 1 x 5 mm slice of a plug 
was transferred into the SmaI restriction digest mixture which consisted of 1 µl BSA 
(BioLabs, New England), 30U SmaI (Roche Diagnostics, Germany) and 1X SmaI restriction 
buffer in a final volume of 128 µl. The plugs were then incubated at 25°C for 3 hours. 
As outlined in A4.6, 150 ml of 1% (w/v) Biorad Ultrapure Molecular Grade Agarose gel (Bio-
Rad Laboratories, California, USA) was prepared and equilibrated at 60°C for 10 min. The 
agarose was poured into the gel tray and allowed to set for 2.5 hours. Two and a half litres 
of 0.5X TBE [A4.7] was transferred into the cooling unit of the PFGE apparatus (Gene 
NavigatorTM System, Amersham Biosciences AB, Sweden)  and allowed to chill at 4°C for 2.5 
hours. 
Following the restriction digest, the plugs were carefully loaded on the gel and the wells 
sealed with 1% (w/v) Seakem Gold Agarose gel [A4.2]. The PFGE components were 
assembled and the programme parameters set as follows: 5 s initial switch time, 30 s final 
switch time, 20-hour duration run, 200V and chiller at 14°C.  
For visualisation of the restriction digest profiles, the gel was placed in a container to which 
500 ml of the running buffer with 1 mg/ ml EtBr had been added.  The container was placed 
on a rotor set at 30 rpm for 30 min. The gel was destained in 400 ml distilled water using the 
rotor set at 30 rpm for 15 min, and then viewed under UV light.  
Analysis of the PFGE profiles was carried out visually. 
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4.4 Results 
4.4.1 Synchronization of the initial inocula 
The initial inocula for the test strains were synchronized to exponential phase based on OD 
600 nm measurements over time [4.3.2.1]. Initially the cells were cultured to stationary 
phase revealing exponential growth for all strains between two and three and a half hours, 
as indicated in Fig 4.5, at OD values ranging between 0.3 and 0.8. 
              
Figure 4.5: The growth parameters of the individual strains, based on 0D 600 nm measurements over time. For 
all strains, the exponential growth occured between 2 and 3.5 hours, as indicated by the grey bar on the graph.  
 
The second step of synchronisation involved culturing the cells for three hours [4.3.2.2], 
after which, the experiment was stopped at the  OD values indicated in Table 4.2. Based on 
the average of duplicate cultures (Fig 4.1) viable cell counts [A3.1] of the exponential phase 
cells were determined (Table 4.2). 
 
 
 
 
 
D4 
E3 
E8 
S5 
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Table 4.2: OD 600 nm measurements and the viable cell count at exponential phase (3 hours). 
 
4.4.2 Comparison of the growth kinetics of the resistant strains relative to MS14 
The growth kinetics of the individual strains were compared based on turbidity at OD 600 
nm over a 24-hour period. As depicted in Fig 4.6, while the resistant strains had a slightly 
longer lag phase (six to eight hours) in comparison to MS14 (five hours), the exponential 
phase for all strains was in the range OD 0.2 – OD 0.6. 
 
 
Figure 4.6: Comparative growth rates between ST612-MRSA-IV strains and MS14 over a 24-hour period. The 
exponential phase of the strains is indicated in grey on the graph, the values of which were used to compare 
the growth rates of the resistant strains relative to MS14.  
 
S. aureus isolates Viable cell count (3 hours) 
OD 600 nm Average number of 
colonies 
Total dilution factor CFUml
-1 
MS14 0.609 57 10
7 
5.7 x 10
8 
ST612-MRSA-IV D4 0.441 23 10
7
 2.3 x 10
8 
E3 0.479 35 10
7
 3.5 x 10
8 
E8 0.473 54 10
6
 5.4 x 10
7 
S5 0.451 21 10
7
 2.1 x 10
8 
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Using the OD 600 nm values, 0.2 - 0.6, which represent exponential growth of the strains as 
shown in Fig 4.6, the growth rates (µ) of the individual strains were calculated using the 
formula, µ = [lnNt-lnN0]/ (t-t0) (Table 4.3).  
Table 4.3: The growth rates calculated based on OD 600 nm measurements at exponential phase (0.2 – 0.6) of 
the individual strains. 
Isolate                                       µ = [lnNt-lnN0]/ (t-t0) Average growth rate ± SD
a
 
A B C D E F 
MS14 0.414 0.524 0.434 0.429 0.408 0.443 0.442 ± 0.042 
D4 0.494 0.415 0.493 0.397 0.543 0.586 0.488 ± 0.073 
E3 0.402 0.392 0.437 0.423 0.479 0.466 0.433 ± 0.035 
E8 0.494 0.508 0.503 0.593 0.603 0.478 0.530 ± 0.054 
S5 0.102 0.323 0.385 0.262 0.294 0.336 0.284 ± 0.098 
µ = [lnNt-lnN0]/ (t-t0); where N represents OD 600 nm values at two time points (t) over which growth 
increased exponentially. A, B, C, D, E, F, growth rates of the strains calculated per individual culture.  
a 
Exponential growth rate of individual strains represented as a mean of six independent cultures per isolate ± 
standard deviation. 
 
A bar graph of these data (Fig 4.7) indicates that there was no significant difference in the 
growth rates between MS14, D4, E3 and E8. S5, on the other hand, grew more slowly. 
   
          
 
Figure 4.7: The average growth rates of the strains. Average growth rates, with error bars (mean ± standard 
deviation), were calculated based on growth of the strains at exponential phase (OD 0.2 – OD 0.6) as depicted 
in Fig 4.6. Each value represents the mean of six independent cultures per isolate. 
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4.4.3 Pairwise competition assays between S. aureus strains 
4.4.3.1 Twenty four-hour pairwise competition assays between MS14 and ST612-
MRSA-IV 
Pairwise competition assays between MS14 and each of the resistant strains were carried 
out, over a 24-hour period [4.3.4.1].  As shown in Fig 4.8, there was no difference in the 
bacterial cell count between MS14 and each of the resistant strains for the first 10 hours of 
growth, with the bacterial cell count in the individual paired experiments increasing from 
the initial inocula (Table 4.4) to a maximum of 109 CFUml-1 for all the strains (Table A3.2.1).  
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Figure 4.8: The pairwise competition assays between MS14 and ST612-MRSA-IV strains, carried out over a 24-
hour period. The viable cell count of the susceptible strain in each assay was calculated by subtracting the 
viable cell count of the resistant strain from the total viable cell count in the mixed culture. Each assay was 
carried out in duplicate and the data represented as an average of the two experiments.   
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During the subsequent 14 hours of growth, the bacterial cell count for MS14, E3 and S5 
remained at 109 CFUml-1 while D4 and E8 cell counts decreased to 108 CFUml-1 (Fig 4.8).  
Similar results were obtained when the ratio of CFUs for each individual strain was obtained 
at the beginning (t0) and the end (t24) of the assay (Table 4.4).  
 
Table 4.4: Ratio of ST612-MRSA-IV and MS14 in the 24-hour pairwise competition assays 
 
 
t, time, in hours, of sampling following incubation at 37°C. CFUml
-1
 values presented as a mean of two 
separate experiments. 
 
 
When the cell counts obtained at t0 and t24 for the resistant isolates were divided by the 
corresponding counts obtained for MS14, the ratio between D4 and MS14 remained 
relatively constant after 24 hours. On the other hand, there were respective 2-fold and 30-
fold decreases in E3 and E8, and a 4-fold increase in the cell count of S5, when compared to 
MS14 (Table 4.4).   
4.4.3.2 Five-day pairwise competition assays between MS14 and ST612-MRSA-IV 
Five-day serial passages of the pairwise competition assays were carried out [4.3.4.2]. The 
bacterial cell count for all the resistant strains remained relatively similar to the respective 
count of MS14 in the paired assays for the first 24 hours, growing from the initial inocula 
(Table 4.5) to the final count of 109 CFUml-1 for all strains (Fig 4.9). 
Isolate ST612-MRSA-IV CFUml
-1
  MS14 CFUml
-1 
Ratio ST612-MRSA-IV/MS14 
(CFUml
-1
) 
Initial CFUml
-1 
(t0) 
Final CFUml
-1 
(t24) 
Initial CFUml
-1 
(t0) 
Final CFUml
-1 
(t24) 
Initial ratio 
(t0) 
Final ratio (t24) 
D4             6.0 x 10
3 
7.2 x 10
8 
2.2 x 10
4 
           3.7 x 10
9 
0.27 0.19 
E3 1.5 x 10
4 
1.2 x 10
9 
1.7 x 10
4 
2.9 x 10
9 
0.88 0.41 
E8 9.0 x 10
3 
1.2 x 10
8 
1.0 x 10
4 
4.1 x 10
9 
0.90 0.03 
S5 6.0 x 10
3 
3.4 x 10
9 
2.6 x 10
4 
4.0 x 10
9 
0.23 0.85 
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Figure 4.9: The growth curves for pairwise competition assays between ST612-MRSA-IV strains and MS14 
during five-day serial passage experiments. The viable cell count of the susceptible strain in each assay was 
calculated by subtracting the viable cell count of the resistant strain from the total viable cell count in the 
mixed culture. Each assay was carried out in duplicate and the data represented as an average of the two 
experiments.   
 
However, the cell count for three of the resistant strains (E3, E8 and S5) began to decrease 
from between day two and day four in comparison to MS14 (Table A3.2.2). The colony 
count of D4 remained similar to MS14 at 109 CFUml-1 (Fig 4.9). By day five of the 
experiments, E8 and S5 had each decreased to 108 CFUml-1 while the cell count for E3 
decreased to 107 CFUml-1. In each of these assays, MS14 remained constant at 109 CFUml-1 
but increased to 1010 CFUml-1 when paired with E3. These findings were reflected in the end-
point analyses of the competition assays (Table 4.5), in which the ratio of D4 to MS14 
remained the same throughout the five-day assay, while significant differences were 
reflected in the ratios of E3, E8 and S5 to MS14 in the respective assays.  
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Table 4.5: Ratio of ST612-MRSA-IV to MS14 in the five-day pairwise competition assays 
Isolate ST612-MRSA-IV CFUml
-1
  MS14 CFUml
-1
 Ratio ST612-MRSA-IV/MS14 
(CFUml
-1
) 
Initial CFUml
-1 
(t0) 
Final CFUml
-
1 
(t5) 
Initial CFUml
-1 
(t0) 
Final CFUml
-1 
(t5) 
Initial ratio 
(t0) 
Final ratio 
(t5) 
D4    8.25 x 10
3 
4.35 x 10
9 
1.55 x 10
4 
4.45 x 10
9 
0.53 0.977 
E3 1.44 x 10
4 
5.00 x 10
7 
1.34 x 10
4 
9.70 x 10
9 
1.07 0.005 
E8          1.13 x 10
4 
9.50 x 10
8 
1.02 x 10
4 
5.95 x 10
9 
1.11 0.160 
S5 1.35 x 10
4
  1.25 x 10
8 
1.09 x 10
4 
9.53 x 10
9 
1.24 0.013 
t, time, in days, of sampling following incubation at 37°C. CFUml
-1
 values presented as a mean of two separate 
experiments. 
 
At the end of the five-day assays, there was a seven-fold decrease in E8 cell numbers in 
comparison to MS14 while E3 decreased by 200-fold (Table 4.5). A 95-fold decrease in the 
cell count of S5 was significantly different from the four-fold increase observed for this 
isolate for the 24-hour assay. 
4.4.3.2.1 Relative fitness of MS14 in comparison to ST612-MRSA-IV 
The relative fitness of MS14, in comparison to its resistant counterparts, was calculated 
based on the five-day pairwise competition assays. Using the formula, relative fitness (RF) = 
average generation number of resistant strains (gR) / average generation number of 
susceptible strains (gS) [4.3.4.3], there were no significant differences in the relative fitness 
of D4 and MS14 over the five days (Fig 4.10). After the first 24 hours, a similar result applied 
to E3, E8, and S5. However, relative to MS14, the fitness of E3 and S5 decreased daily over 
the five-day period to approximately 0.6 (Fig 4.10). Although the relative fitness of E8 
remained constant for four days, it decreased to 0.8 by day five (Fig 4.10). 
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Figure 4.10: The relative fitness of MS14 in comparison to the resistant strains, D4, E3, E8 and S5. Relative 
fitness was calculated, every 24 hours, as the ratio between the average number of generations of the 
individual resistant strains and MS14 for the duration of the five-day competition assays (Table A3.2.3). Each 
assay was carried out in duplicate. 
 
For the duration of the assay, there were no differences in the relative fitness of D4 and 
MS14 (Fig 4.10). On the other hand, the relative fitness of E3 and S5 decreased over the five 
day period, to approximately 0.6 on day five, for both strains, relative to MS14. Although 
the relative fitness of E8 remained relatively constant for four days, it decreased to 0.8 by 
day five (Fig 4.10). 
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4.4.4 PFGE profiles of MS14, D4, E3, E8 and S5  
 
Analysis of the PFGE profiles of MS14 and the resistant isolates indicated that MS14 is more 
closely related to D4 than to E3, E8 and S5 (Fig 4.11). Isolate D4 contains a SmaI fragment 
which is absent in MS14, while the latter contains a doublet immediately below the missing 
fragment (Fig 4.11).  It is assumed these differences result from the partial excision of 
SCCmec IV; this could be confirmed by Southern blot hybridisation using mecA as a probe. 
  
                           
Figure 4.11: SmaI restriction profiles of MS14 and ST612-MRSA-IV isolates, D4, E3, E8 and S5. Yellow arrow 
shows a fragment present in D4 but absent in MS14.  
 
 
 
 
 
 
 
 
         MS14            D4             E3              E8               S5 
A shift in the bands to 
form doublet fragments 
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4.5 Discussion 
Acquisition and basal expression of mecA imposed a fitness cost on S. aureus strains in the 
studies by Ender, McCallum et al. (2004), Lee, Ender et al. (2007), Collins, Rudkin et al. 
(2010) and Noto, Fox et al. (2008). Partial deletion of SCCmec, notably the deletion of mecA, 
has been associated with fitness advantage in MSSA relative to MRSA and was first 
described by Noto, Fox et al. (2008).  
The relative growth rates of the individual strains were compared based on turbidity 
measurements at OD 600 nm. Compared with the growth rate of MS14, all of the resistant 
strains had longer lag phases; however, the exponential growth rates of D4, E3 and E8 were 
the same as MS14 (Fig 4.7). On the other hand, the growth rate of S5 was slower than the 
corresponding rate of MS14. A lack of consensus in exponential growth rates of resistant 
strains compared to their susceptible counterparts w s also observed in a study by Noto, et 
al. (2008) in which one of three MSSA strains grew faster than its MRSA counterpart. In their 
study, the authors compared exponential growth phase doubling times between three 
vancomycin resistant MSSA strains, two with partial SCCmec II and one (5836VR) with site-
specifically excised SCCmec II, and their vancomycin resistant MRSA counterparts. A non-
significant difference in the doubling times of the MSSA strains and their MRSA counterparts 
was observed; on the other hand, complete excision of SCCmec resulted in improvement in 
the growth rates of 5836VR. The reasons for the differences in the growth rates within D4, 
E3, E8 and S5, and between the individual resistant isolates, and MS14 are unknown and 
may be unrelated to the presence or absence of mecA. As a measure of fitness of strains, 
the comparison of exponential growth rates alone is a poor yardstick as it fails to index the 
global fitness of the strains throughout their growth cycle (Noto, Fox et al. 2008).  
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Based on the exponential phase growth rates of the individual strains, in which S5 was 
dividing at a slower rate than MS14 while D4, E3 and E8 grew at similar rates as the 
susceptible counterpart, MS14 could be expected to outcompete S5 but compete 
successfully with D4, E3 and E8. However when the individual resistant strains and MS14 
were competed over 24 hours, S5, with a four-fold increase in cell numbers at 24 hours 
revealed a slight competitive advantage over MS14 (Fig 4.8). On the other hand, respective 
two-fold and 30-fold decreases in E3 and E8 suggest that MS14 is more competitive with 
respect to these resistant strains. No fitness differences were observed between MS14 and 
D4 (Fig 4.8).  
With the exception of D4, differences in the viable cell counts, only detected after 24 hours, 
between MS14 and the resistant strains, were mirrored in a study by Ender, McCallum et al. 
(2004) in which MRSA SCCmec type I strains and their isogenic MSSA counterparts were 
competed. After the 24 hours there was no significant difference in the cell counts of the 
strains investigated (Ender, McCallum et al. 2004). By extending the experiment, Ender, et 
al. were able to determine differences in viable cell counts of the competing strains on day 
six. In this light, pairwise competition assays were carried out to investigate competition 
between MS14 and the resistant strains over five days, during which time cell cultures were 
passaged every 24 hours. After five days MS14 outcompeted E3 and S5 as indicated by the 
respective 200-fold and 95-fold decreases in the final cell counts of the resistant strains. 
Although at 24 hours there was no significant difference in the fitness of both strains 
relative to MS14, there was steady decrease in the fitness of these strains by day five (Fig 
4.10). In contrast, E8 was the outlier; relative to MS14, it remained fit for four days before it 
was outcompeted by MS14 based on the seven-fold decrease in E8. Ender, McCallum et al. 
(2004) reported similar findings in which susceptible S. aureus strains outcompeted their 
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isogenic MRSA SCCmec type I counterparts, but at different rates. Although it cannot be 
assumed that the presence of SCCmec IV was responsible for the poor survival of the ST612-
MRSA-IV strains, it is possible to suggest that the mec imposes a fitness cost on these 
strains. 
As was observed in the growth rates of D4 in both the 24-hour and five-day competition 
assays (Fig 4.8 and Fig 4.9), there was no difference in the relative fitness of this isolate 
compared to MS14. Thus the presence of SCCmec IV in D4 did not appear to impose a 
fitness cost on this resistant strain and it may be that D4 has evolved, possibly by the 
acquisition of a fitness-compensatory mutation, to accommodate SCCmec IV in its genome. 
In bacterial populations, expansion of a particular clone in a specific environment is 
preceded by a population bottleneck which selects for the persistence of strains which are 
best fitted for a particular environment. Often, this is evidenced by a reduction in the 
genetic diversity of the population (Spratt and Maiden 1999). The study of Jansen van 
Rensburg, Madikane et al. (2011) showed that, based on PFGE and spa typing, cluster E was 
more genetically diverse than cluster D. On the evolutionary scale, cluster E may be more 
recent than D. As PFGE indicated that MS14 is more closely related to D4 than to the other 
resistant counterparts, it is perhaps not surprising that this isolate competed successfully 
with D4. 
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5. CONCLUDING COMMENTS 
The studies carried out by Jansen van Rensburg, Madikane et al. (2011) led to the suggestion 
that ST612-MRSA-IV may have arisen locally. To the best of the author’s knowledge, there 
have not been any reports of ST612-MSSA. The best strategy to determine whether ST612-
MRSA-IV may have arisen locally would have been to analyse a longitudinal collection of 
MSSA isolates that preceded the emergence of ST612-MRSA-IV; regrettably no such 
collection was available and therefore, MSSA isolates contemporaneous with the previously 
characterized MRSA were screened for the presence of ST612-MSSA. Using spa typing and 
MLST, one ST612-MSSA-t064 isolate, MS14, was identified among 19 MSSA isolates.  
Interestingly, this isolate contained remnants of SCCmec, including dcs, within the attB site, 
suggesting that it may have resulted from a CcrABC ind pendent and partial excision of 
SCCmec from a corresponding ST612-MRSA strain. This partial deletion of SCCmec has 
recently been described in clinical isolates of S. aureus (Donnio, Louvet et al. 2002; Donnio, 
Oliveira et al. 2005; Donnio, Fevrier et al. 2007; Noto, Fox et al. 2008; Shore, Rossney et al. 
2008). The detection of uncommon amino acid substitutions, associated with rifampicin 
resistance, in RpoB, as well as a unique single nucleotide polymorphism in the RRDR of 
MS14, previously identified in ST612-MRSA-IV isolates (Jansen van Rensburg, Eliya Madikane 
et al. 2011) suggested that MS14 resulted from a partial loss of SCCmec from a 
corresponding ST612-MRSA. 
Noto, Fox et al. (2008) associated partial loss of SCCmec with an increase in fitness in the 
resulting strains. This led the author to consider the possibility that MS14 could be fitter 
than ST612-MRSA-IV. Comparison of the exponential growth rate of MS14 with those of 
representative ST612-MRSA-IV isolates, D4, E3, E8 and S5, proved to be a poor measure of 
fitness when compared to the results of the competition assays. This accords with the data 
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of Noto, Fox et al. (2008) who noted the importance of indexing the global fitness of strains 
throughout their growth cycle when ascertaining their fitness. Competition between the 
resistant strains and MS14 was investigated with 24-hour and five-day assays. The 24-hour 
assays also proved to be poor yardsticks to determine the comparative fitness of the strains, 
as they revealed minor differences between MS14 and the resistant strains and, only during 
the stationary phase. As was observed by Ender, et al. (2004), extending the competition 
assays to five days proved more informative. By day five the cell numbers of E3, E8 and S5, 
had decreased 200-fold, seven-fold and 95-fold, respectively, indicating poor survival of 
these resistant isolates when compared to the survival of MS14. Since cost to fitness has 
been described for strains containing SCCmec (Ender, McCallum et al. 2004; Lee, Ender et al. 
2007; Collins, Rudkin et al. 2010; Noto, Fox et al. 2008), it may be that the carriage of 
SCCmec IV by E3, E8 and S5 exerts a similar cost.  The possibility of other factors, besides 
carriage of SCCmec IV, contributing to differences in the relative fitness of the resistant 
strains cannot be excluded. 
However, the survival of D4 in comparison to MS14 suggests that the two isolates are 
equally fit. Evidence from PFGE experiments carried out in the current study suggest a closer 
relatedness of MS14 to D4 than to its E counterparts and S5, suggesting that D4 may have 
evolved, possibly through acquisition of fitness-compensatory mutations, to accommodate 
the mec.   
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
112 
 
Appendices 
A1 
A1.1 Preparation of 2YT broth 
To make 1L broth: 
 Measure out about 900ml RO water 
 Add 16g Bacto Tryptone 
 Add 10g Bacto Yeast Extract 
 Add 5g NaCl 
 Adjust to pH7 with NaOH 
 Make up to 1000ml with RO water 
 Autoclave 
 
A1.2 Preparation of 2YT agar 
To make 1L agar: 
 Measure out about 900ml RO water 
 Add 16g Bacto Tryptone 
 Add 10g Bacto Yeast Extract 
 Add 5g NaCl 
 Add 15g Bacteriological agar 
 Adjust to pH7 with NaOH 
 Make up to 1000ml with RO water 
 Autoclave 
 
A1.3 Preparation of 50% glycerol stocks 
To make 1ml stock: 
 Add 250 µl glycerol to 250 µl RO water, autoclave solution then store at room 
temperature. 
 Streak the sample onto agar, to separate into single colonies, then incubate 
sample at 37°C overnight. 
 Inoculate 1 colony into broth media and culture at 37°C overnight. 
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 Aliquot 500 µl of the overnight culture onto the 50% glycerol solution (warmed 
to 37°C), mix thoroughly and then store at -80 °C. 
A2 
 
A2.1 Microbial growth analysis using Bioscreen C Microbiological Reader 
 
1. Load samples onto 100-well Honeycomb plate 
                  
2. Transfer plates into the incubation chamber on the Bioscreen C reader 
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3. Activate the Bioscreen C reader using the Research Express software 
 
 
4. View microbiological calculations in progress using the Research Express software  
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A3 
 
A3.1 Calculation of CFUml-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Number of colonies/ dilution 
104 105 106 
MS14 Plate 1 TNTC 57 7 
Plate 2 TNTC TNTC 14 
Average number of colonies TNTC 57 11 
D4 Plate 1 214 14 2 
Plate 2 TNTC 32 6 
Average number of colonies 214 23 4 
E3 Plate 1 236 23 6 
Plate 2 TNTC 46 4 
Average number of colonies 236 35 3 
E8 Plate 1 41 1 1 
Plate 2 66 18 0 
Average number of colonies 54 10 1 
S5 Plate 1 194 22 2 
Plate 2 210 19 1 
Average number of colonies 202 21 2 
Sample Average # colonies Initial dilution factor Total dilution factor CFU/ml 
MS14 57 105 107 5.7 X 108 
D4 23 105 107 2.3 X 108 
E3 35 105 107 3.5 X 108 
E8 54 104 106 5.4 X 107 
S5 21 105 107 2.1 X 108 
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A3.2 Results of the competition assays 
 
Table A3.2.1 Results of the 24 h assays, presented as an average of two experiments 
hours D4 + MS14 E3 + MS14 E8 + MS14 S5 + MS14 D4 E3 E8 S5 MS14(D4) MS14(E3) MS14(E8) MS14(S5) 
0 2.80E+04 3.20E+04 1.90E+04 3.20E+04 6.00E+03 1.50E+04 9.00E+03 6.00E+03 2.20E+04 1.70E+04 1.00E+04 2.60E+04 
4 1.20E+07 1.00E+07 1.00E+07 9.00E+06 5.90E+06 1.80E+06 4.50E+06 1.80E+06 6.10E+06 8.20E+06 5.50E+06 7.20E+06 
6 3.60E+08 2.10E+08 1.90E+08 3.20E+08 1.27E+08 4.30E+07 4.30E+07 6.20E+07 2.33E+08 1.67E+08 1.47E+08 2.58E+08 
10 8.40E+09 8.00E+09 7.70E+09 6.80E+09 1.47E+09 1.33E+09 1.58E+09 1.40E+09 6.93E+09 6.67E+09 6.12E+09 5.40E+09 
24 4.40E+09 4.10E+09 4.20E+09 7.40E+09 7.20E+08 1.20E+09 1.20E+08 3.40E+09 3.68E+09 2.90E+09 4.08E+09 4.00E+09 
 
 
Table A3.2.2 Results of the 5 day assays, presented as an average of two experiments 
 
 
 
 
 
 
 
day D4 + MS14 E3 + MS14 E8 + MS14 S5 + MS14 D4 E3 E8 S5 MS14(D4) MS14(E3) MS14(E8) MS14(S5) 
0 2.37E+04 2.78E+04 2.15E+04 2.44E+04 8.25E+03 1.44E+04 1.13E+04 1.35E+04 1.55E+04 1.34E+04 1.02E+04 1.09E+04 
1 9.45E+09 9.80E+09 1.12E+10 9.10E+09 4.95E+09 3.65E+09 6.75E+09 5.40E+09 4.50E+09 6.15E+09 4.45E+09 3.70E+09 
2 1.15E+10 7.55E+09 1.13E+10 1.15E+10 5.40E+09 1.30E+09 4.05E+09 4.65E+09 6.05E+09 6.25E+09 7.25E+09 6.85E+09 
3 1.16E+10 1.10E+10 7.00E+09 7.35E+09 3.70E+09 2.50E+08 4.70E+09 7.00E+08 7.85E+09 1.07E+10 2.30E+09 6.65E+09 
4 9.35E+09 1.10E+10 7.58E+09 1.06E+10 5.70E+09 2.95E+08 2.43E+09 1.17E+09 3.65E+09 1.07E+10 5.15E+09 9.38E+09 
5 8.80E+09 9.75E+09 6.90E+09 9.65E+09 4.35E+09 5.00E+07 9.50E+08 1.25E+08 4.45E+09 9.70E+09 5.95E+09 9.53E+09 
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Table A3.2.3 Average generation numbers of the strains for the 5 day assays 
 Average Generation number  
day D4 + MS14 D4 MS14 
0 0 0 0 
1 19.15 19.98 18.58 
2 19.42 20.11 19.02 
3 19.44 19.57 19.40 
4 19.14 20.17 18.25 
 5 18.86 19.16 18.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average Generation number 
day                  E3 + MS14 E3 MS14 
0 0 0 0 
           1  19.15 19.98 18.58 
           2  19.42 20.11 19.02 
           3  19.44 19.57 19.40 
           4  19.14 20.17 18.25 
           5  18.86 19.16 18.56 
 Average Generation number  
   day E8 + MS14 E8 MS14 
0 0 0 0 
1 19.51 19.49 19.69 
2 19.53 18.67 20.29 
3 18.82 18.97 18.70 
4 18.92 18.02 19.76 
5 18.83 16.23 20.13 
   Average Generation number  
day S5 + MS14 S5 MS14 
0 0 0 0 
1 18.91 18.89 18.88 
2 19.30 18.64 20.10 
3 18.57 15.43 20.01 
4 19.17 16.32 20.57 
5 18.96 13.13 20.51 
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A4 
 
A4.1 Preparation of TEN buffer 
 20 ml  1M Tris 
 40 ml 0.5M EDTA 
 6 ml 5M NaCl 
 Make up to 200 ml with H2O 
 Adjust to pH7.5 and then autoclave 
 
A4.2 Preparation of Seakem Gold AGarose gel 
To make 1.8%: 
 1.8 g Seakem Gold Agarose  
 100 ml TE buffer 
 Homogenise and then equilibrate at 60°C 
 
A4.3 Preparation of EC buffer 
 0.5% Sarkosyl 
 0.5% Brij 
 0.1M EDTA 
 1M NaCl 
 0.006M Tris 
 Use H2O as diluent, adjust to pH7.5 and then autoclave 
 
A4.4 Preparation of ESP buffer 
 10mM Tris-HCl 
 1mM EDTA 
 1% SDS 
 1 mg/ml Proteinase K 
 Use H2O as diluent, adjust to pH8.0 and store at -20°C 
 
A4.5 Preparation of TE buffer 
 10 ml 1M Tris 
 2 ml 0.5M EDTA 
 Make up to 1000ml with H2O 
 
A4.6 Preparation of 1% Biorad Ultrapure Molecular Grade Agarose gel 
 1.5 g Biorad Biorad Ultrapure Molecular Grade Agarose  
 150 ml 0.5X TBE buffer 
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A4.7 Preparation of TBE 
To make 10X TBE: 
 108 g Tris Base 
 55 g Boric Acid 
 40 ml 0.5M EDTA (pH8.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
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